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The Hedgehog (Hh) signaling pathway regulates normal development and 
cell proliferation across the metazoa. Upon its aberrant activation, mammalian 
Hh signaling can also cause tumor formation. Hh-induced tumors can arise from 
different tissues and can be locally invasive but rarely metastatic or highly 
aggressive, as is the case with basal cell carcinoma (BCC) of the skin and the 
cerebellar tumor medulloblastoma (MB), respectively. Little is known about 
common cell-intrinsic factors that control the development of such diverse Hh-
dependent tumors. The zinc-finger transcription factor Zfx is required for the self-
renewal of several stem cell types in both mouse and human, but its role in 
malignant transformation remains controversial. We found that Zfx is variably 
required for the development of two distinct Hh-dependent tumors in vivo. Co-
deletion of Zfx prevented BCC formation initiated by Hh pathway overactivation in 
the skin following deletion of the inhibitory receptor Ptch1. Co-deletion of Zfx also 
  
delayed development of Hh-dependent MB caused by Ptch1 deletion in vivo. In 
contrast, Zfx was dispensable for the development of the PTEN-dependent brain 
tumor glioblastoma, showing that a requirement for Zfx is not generalizable 
across all cancers. We used genome-wide expression and chromatin binding 
analysis in a human MB cell line to identify direct, evolutionarily conserved 
targets of Zfx. These targets included the Hh signal transducer Smoothened 
(Smo). Smo expression data from Zfx-deficient BCC and MB cells in vivo and in 
vitro suggest that Zfx may directly regulate Hh pathway activation in some 
cancers. We identified two additional conserved downstream targets of Zfx, 
Dis3L and Ube2j1, which were required for optimal growth of human MB cells in 
vitro. These results identify Zfx as a common cell-intrinsic regulator of diverse 
Hh-induced tumors. Further investigation of the requirement for Zfx and its 
conserved downstream target genes, such as Dis3L and Ube2j1, in in vivo 
models of Hh-dependent BCC and MB could lead to the identification of novel 
targetable molecules for therapies directed against these malignancies. 
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Tissue stem cells, developmental signaling pathways, and cancer 
 A hallmark of cancer is the aberrant acquisition, continuation, or 
reactivation of a self-renewal program more properly restricted in a mature 
organism only to tissue-regenerating adult stem cells. It is perhaps not surprising, 
then, that the cell-of-origin for a growing number of cancers is thought to reside in 
stem-and-progenitor compartments 1. In the hematopoietic system, chronic 
myelogenous leukemia (CML) driven by BCR-Abl is thought to initiate from 
hematopoietic stem cells (HSC) exclusively 1, and models of acute myeloid 
leukemias (AML) suggest that they too originate in stem cells or early 
uncommitted progenitors 1-3. Examples also abound in solid tumors. Intestinal 
adenomas have been suggested to arise from the various Lgr5+, prominin+, and 
Bmi1+ cells identified as intestinal stem cells in intestinal crypts 4-6. In the skin, 
the cell-of-origin for the common tumor basal cell carcinoma (BCC) is thought to 
dwell in the stem/progenitor compartment of the hair follicle, the hair follicle bulge 
7, 8, or in a pool of resident progenitor cells in the interfollicular epidermis 9. In the 
brain, mouse models have demonstrated that different subtypes of the cerebellar 
tumor medulloblastoma (MB) originate in proliferating precursor cells on the 
surface of the developing cerebellum 10, 11 or in the dorsal brainstem 12. 
 A common etiology among cancers is the aberrant activation of one of the 
handful of evolutionarily conserved, intercellular signaling pathways critical for 
normal embryonic development - - such as the Wnt pathway, the Notch pathway, 
and the Hedgehog (Hh) pathway, to name a few examples. Frequently, the 
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pathway whose activation causes the cancer will have also played a vital role in 
the normal development of the cell-type or tissue from which the cancer derives. 
For example, Wnt signaling is required for intestinal crypt stem cell self-renewal 
and long-term maintenance of crypts in the intestine, and mutations in Wnt 
pathway components APC and β-catenin have long been causally linked with 
intestinal cancer 13. In the case of T-cell acute lymphoblastic leukemia (T-ALL), 
over half of T-ALL cases stem from activating mutations in the NOTCH1 receptor 
14, 15, and Notch1 is also critical for early T-cell development in the thymus 16, 17. 
Nor is the Hh pathway exempt from this rule. Functional Hh signaling is essential 
for hair follicle morphogenesis in developing murine skin 18, 19, and 
hyperactivation of the Hh pathway is necessary and sufficient for development of 
the follicle-derived tumor BCC in mouse models 20-22. Hh pathway activity is also 
necessary for expansion of proliferating granule neuron precursors (GNP) and for 
full growth and normal foliation in the developing cerebellum 23, 24, and induction 
of uncontrolled Hh pathway hyperactivation in those self-same GNP generates 
the cerebellar tumor MB 10, 11. 
 
The Hedgehog (Hh) signaling pathway 
 The Hh signaling pathway is an intercellular signaling pathway conserved 
across the metazoa and crucially important for a whole host of developmental 
processes, as well as for maintenance of tissues in adult organisms 25, 26. The 
pathway is named for the single ligand hedgehog in the fruit fly Drosophila 
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melanogaster, which was first identified in a screen for segment polarity genes in 
the Drosophila embryo 27. In contrast, the Hh pathway has three diffusible 
extracellular ligands in mammals - - Sonic hedgehog (Shh), Desert hedgehog 
(Dhh), and Indian hedgehog (Ihh) - - of which Shh is the most widely expressed 
and consequently has the larger number of developmental processes that 
depend upon it 26. The core components of the mammalian Hh pathway 
downstream of the Hh ligand are diagrammed below in Figure 1.  
 Hh protein is initially translated as a 45 kDa peptide, but it undergoes an 
autoproteolytic cleavage event that processes it into its truncated extracellular 
ligand form, with the N-terminal fragment of cleaved Hh (HH-N) bearing the 
signaling functionality 25, 28. HH-N is also subjected to post-translational lipid 
modifications, including palmitoylation at its N-terminus 29, 30 and addition of a 
cholesterol moiety at its C-terminus 25, 31, 32. Lipid-modified HH-N is secreted into 
the extracellular milieu by the membrane protein Dispatched 33-35, where its 
cholesterol-modification is thought to be crucial for the long-range dispersal of Hh 
ligand 25, 36 that allows for formation of the gradients of Hh signal integral in Hh-
dependent developmental processes. 
Graded Hh signal is received by the receptor and 12-pass transmembrane 
protein, Patched (Patched1, or Ptch1, in mammals). In vertebrates, Hh ligand 
binds to two large extracellular domains of Ptch1 25, 37 with the assistance of 
transmembrane co-receptors CDO and Brother of CDO (BOC) 38. Somewhat 
unusually, the Hh receptor Ptch1 is an inhibitory receptor. In the absence of any 
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extracellular Hh ligand, Ptch1 functions by inhibiting a downstream signal 
transducer of the Hh pathway. Binding of Hh ligand then inhibits the inhibitory 
receptor Ptch1, freeing the downstream pathway for activation. 
 Downstream of Patched, the single, non-redundant signal transducer of 
the Hh signaling pathway is Smoothened (Smo). Smo encodes a 7-pass 
transmembrane protein that is a member of the G-protein coupled receptor 
protein family, although it does not appear to function as a receptor or interact 
with G-proteins 25, 39. Knockouts of Smo have confirmed that Smo is essentially 
required in both invertebrates and in vertebrates for Hh pathway activity 40-44. The 
precise molecular mechanisms governing upstream Ptch1 inhibition of Smo, as 
well as the effect of Smo on downstream GLI-type transcriptional effectors of the 
Hh pathway, remain mysterious and incompletely understood. However, it is 
clear that, in the absence of signal from extracellular Hh ligand, Ptch1 
catalytically inhibits Smo (without direct protein-protein interaction) 45. Upon Hh 
ligand binding and inhibition of Ptch1, Smo is freed from upstream inhibition. 
Notably, in cases where Ptch1 is inactivated by mutation, Smo is permanently 
released from upstream inhibition, in ligand-independent fashion. In vertebrates, 
once Ptch1 is inhibited, Smo is subsequently translocated to a primitive 
organelle, the primary cilium, where its accumulation is essential for downstream 
Hh pathway activation 25, 46, 47. Induction of the Hh pathway via graded Hh signal 
also activates Smo by leading to phosphorylation of and dimerization of the 
cytoplasmic tails of Smo 48. 
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Inhibition of Ptch1 by Hh ligand binding and translocation of Smo to the 
primary cilium lead to activation of GLI proteins, the transcriptional effectors of 
the Hh pathway.25 In mammalian systems, in the absence of Hh ligand and while 
Smo remains inhibited by Ptch1, the GLI-type transcription factors Gli2 and Gli3 
are proteolytically processed into truncated transcriptional repressor forms, with 
Gli2 and Gli3 acting as weak and strong transcriptional repressors, respectively 
25, 49. Association of Gli2 and Gli3 into complexes with suppressor of Fused 
(SUFU) directs the GLI proteins towards processing by the proteasome 50. In 
contrast, when Ptch1 binds Hh ligand, inhibition of Smo is lifted, allowing for Smo 
migration to primary cilia. SUFU-Gli complexes also translocate to the primary 
cilium where Smo activation leads to their dissociation 51, 52, and Gli2 and Gli3 are 
therefore retained in their full-length forms as strong and weak transcriptional 
activators, respectively, driving expression of Hh pathway target genes 25.  
Downstream targets of Gli-mediated Hh pathway transcriptional activation 
include genes favoring proliferation and cell cycle progression like Mycn and 
Ccnd1 and Ccnd2 53, 54. Other known targets include core Hh pathway 
components. This includes the inhibitory receptor Ptch1, which is upregulated 
after pathway activation and attenuates Hh signal gradient by sequestering 
additional Hh extracellular ligand 25. Another Hh pathway component that is also 
a downstream transcriptional target is the GLI-type transcription factor, Gli1, 
which differs from homologs Gli2 and Gli3 in that it only functions as a 
transcriptional activator 25, 55. Gli1 thus represents both a positive feedback 
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mechanism during and also an excellent readout (via measuring of its 
expression) for Hh pathway activation. 
 
 




Figure 1. Core components of the mammalian Hh signaling pathway 
Shown are diagrams depicting the core components of the mammalian Hh 
signaling pathway and their interactions in the absence (A) and presence (B) of 
extracellular Hh ligand signal.  
Diagrams are adapted from Figure 1 of Ng and Curran (2011) 7. 
(A) In the absence of Hh ligand, the inhibitory receptor Ptch1 inhibits Smo, 
allowing downstream SUFU-assisted proteolytic truncation of GLI-type 
transcription factors Gli2 and Gli3 into weak and strong transcriptional repressor 
forms, respectively. 
(B) After detection of Hh ligand by Ptch1, Ptch1 is degraded, removing its 
inhibition of Smo. Smo migrates to primary cilia, where it ultimately effects 
dissociation of SUFU-Gli interactions. Gli2 and Gli3 are retained in their full-
length forms as strong or very weak transcriptional activators, respectively, 
inducing expression of downstream Hh pathway target genes. Among these 
target genes are several core Hh components, including Gli1, which has only a 
transcriptional activator form and generates positive feedback in the context of 
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The Hh signaling pathway and cancer  
A large body of literature exists pointing towards a dependence on Hh 
signaling in multiple solid tumor types 56. Tumor types suggested to require Hh 
signaling range from non-small and small cell lung cancer 57, 58, to glioma 59, to 
melanoma 60, to prostate 61 and pancreatic cancer 62. A cell autonomous function 
via autocrine Hh signaling was originally posited as an explanation for the 
requirement for Hh signaling in these solid tumors. However, a report from Yauch 
et al. (2008) subsequently demonstrated that Hh signaling likely plays a cell 
extrinsic role in these cancers, rather than a cell intrinsic one 56. Xenograft 
models of human tumors in mice where Hh signaling was disrupted (via small 
molecule inhibitor, neutralizing antibody for Hh ligand, or genetic ablation of the 
Hh signal transducer Smo) showed a paracrine requirement for Hh signaling in 
tumor-stroma interactions 56. The cell-extrinsic effects of Hh signaling on different 
solid tumors can be directly relevant to therapy targeting these tumors in 
humans. For example, in the case of pancreatic cancer, Hh signaling from tumor 
to stroma results in decreased vascularization of the tumor, thereby blocking 
ingress of chemotherapeutics and aiding in survival and growth of the cancer 63.  
Beyond cancers that depend on the Hh pathway for tumor-stroma 
interactions, the Hh signaling pathway has also been shown since the mid-1990’s 
to be required cell intrinsically in a handful of human cancers. A cell-intrinsic 
requirement for Hh signaling was first corroborated, for the skin cancer BCC, the 
cerebellar cancer MB, and the skeletal muscle tumor rhabdomyosarcoma, when 
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Gorlin’s Syndrome, a human heritable syndrome conferring predisposition 
towards developing rhabdomyosarcoma, MB, and especially BCC, was linked to 
mutations in the Hh inhibitory receptor Ptch1 64-66. Subsequently, mutations in Hh 
pathway components leading towards pathway activation were found to be 
common in sporadic human BCC and MB as well. It has been estimated that 
~90% of human sporadic BCC bear mutations in PTCH1, with another ~10% 
bearing presumptive activating mutations in SMO 21. Mutations in Hh signaling 
pathway genes define an entire subtype of human MB, comprising ~30% of MB 
cases 67, 68. Mouse models capable of conditionally deleting inhibitory Ptch1 or 
conditionally expressing activated alleles of Smo in the skin and cerebellum 
permitted verification that Hh pathway activation causes BCC and MB 
development in vivo and that Hh-driven BCC and MB originate from stem cells 
and/or progenitors in the hair follicle or developing cerebellum 8, 10, 11, 20. 
 
The role of the transcription factor Zfx in Hh pathway-dependent cancers 
 The transcription factor Zfx is highly conserved in vertebrates and contains 
a C-terminal DNA binding domain, consisting of 13 C2-H2 zinc fingers, and a 
large N-terminal acidic transcriptional activation domain 69. Zfx recognizes a 5-bp 
consensus DNA binding sequence, GGCCT 70-72. Zfx is a member of the small 
Zfy family of transcription factors. The other main member of this family is the Y-
linked Zfy, a gene that was once investigated as a candidate for the male sex-
determining region. Zfy is ubiquitously expressed in human cells but expressed 
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only in tissue-restricted fashion in the testis in mice 73. Encoded on the X 
chromosome, Zfx is ubiquitously expressed in both human and in mouse 73. That 
being said, its actions and any requirements for Zfx are cell-type- and tissue-
specific.  
One of the few known functions for Zfx is in governing a program of self-
renewal across multiple distinct stem cell types. Previously published work from 
our laboratory has demonstrated that Zfx is absolutely required for the self-
renewal of multiple stem cell types 74, 75. Murine embryonic stem cells (ESC) 
bearing a null allele of Zfx (Zfxnull) can differentiate normally. They form tissues of 
all three germinal layers when injected into mice to make teratomas and 
contribute to all tissues in chimeric mice 74. However, Zfxnull ESC are specifically 
deficient in maintaining themselves in an undifferentiated state in vitro 74. Zfxnull 
ESC are outcompeted for growth in undifferentiating conditions by control Zfxflox 
ESC, and Zfxnull ESC exhibit increased apoptosis and decreased growth over 
passages in more restrictive serum-free media 74. Addition of a transgenic copy 
of Zfx into Zfxnull ESC rescued the growth defects in undifferentiated and serum-
free media conditions 74. In other words, Zfxnull ESC are specifically deficient in 
self-renewal.  
Similarly, ZFX is also required for self-renewal in human ESC. Knockdown 
of ZFX in human ESC using lentivirally-delivered RNAi impaired ESC self-
renewal in vitro as measured by clonogenic ESC colony growth 75. In addition, 
overexpression of ZFX in human ESC appears to enhance their self renewal and 
block differentiation in vitro. Human ESC clones overexpressing ZFX from BAC 
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transgenes have enhanced clonogenic colony growth and exhibited reduced 
spontaneous differentiation 75.  
Zfx is also absolutely required for the self-renewal of murine hematopoietic 
stem cells (HSC), the adult stem cell population resident in the bone marrow 
(BM) and responsible for replenishment of the hematopoietic system throughout 
the life of the organism 74. HSC numbers were greatly decreased in mouse BM 
immediately after Zfx was conditionally deleted (ZfxCKO), while myeloid progenitor 
numbers and total BM hematopoietic cell numbers are not affected. ZfxCKO BM 
also fails the gold-standard functional test of HSC self renewal, namely 
reconstitution of hematopoietic lineages after bone marrow transplantation into 
irradiated recipient mice. ZfxCKO BM fails to reconstitute hematopoietic lineages 
over the short- and long-term after competitive BM transplantation, confirming 
loss of HSC self-renewal due to Zfx deletion 74.  Zfx is also required for 
development and maintenance of some more mature hematopoietic lineages. Zfx 
is required for the early development of B lymphocytes and their progression 
through the pro-B to pre-B-cell transition 76. Zfx is also required for the long-term 
homeostatic maintenance of B-cells in peripheral blood and secondary lymphoid 
organs 76.  Loss of Zfx also blocks generation and/or maintenance of B-1 cells, 
an alternative subset of B lymphocytes distinct from the adaptive and memory 
immune responses and capable of self renewal over the course of the organism’s 
lifetime 76. 
While its requirement in the case of stem cell self-renewal is established, 
the role of Zfx in the context of cancer development remains controversial. 
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Several studies have shown virally-delivered RNAi targeted against ZFX 
impairing growth of human laryngeal cancer, glioma, and prostate cancer cell-
lines in vitro 77-79. Unpublished work from our laboratory also points towards a 
requirement for Zfx for initiation and maintenance of AML in vivo (S. Weisberg, 
unpublished data). However, a recent report from a transposon-based screen in 
a MYC-dependent murine liver cancer model found the opposite result, 
identifying Zfx as a potential tumor suppressor gene 80. 
 Here, we present additional evidence in favor of the former view. Given 
that Zfx is required for self-renewal in two distinct types of stem cells, we 
hypothesized that Zfx might also be required for aberrant self-renewal in certain 
cancers. To test this, we utilized models of cancers initiated by Hh signaling 
pathway hyperactivation. Specifically, we observed the effects of Zfx loss in 
mouse models of Hh-dependent BCC and MB generated by conditional deletion 
of inhibitory Ptch1. In Chapter I, we demonstrate Zfx loss prevents Hh-dependent 
BCC development in vivo, suggesting a requirement for Zfx . In Chapter II, we 
present data showing that Zfx loss also delays tumor progression in Hh-
dependent MB in vivo, illuminating a common requirement for Zfx shared across 
two very different Hh-driven cancers. Finally, in Chapter III, we identify conserved 
downstream targets of Zfx in mouse and human, and we pursue preliminary 
investigations of some of the candidate targets, such as the Hh signal transducer 
Smo, to determine their contribution (if any) to the molecular underpinning of the 
requirement for Zfx in Hh-dependent cancers.  
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Hair follicles: morphogenesis and cyclical regeneration 
 Mammalian hair follicles expand and elongate downward into the skin as 
they initially develop and generate hair shafts, and most hair follicles 
subsequently recapitulate this process over and over again through the life of the 
organism in a process of retreat and regrowth called the hair cycle. In the mouse, 
hair follicle morphogenesis begins during embryogenesis and continues into the 
first two post-natal weeks.  Starting when small groups of dermal fibroblasts, 
destined to become dermal papillae, localize beneath basal keratinocytes of the 
embryonic epidermis and help them form into placodes, hair follicle 
morphogenesis continues with proliferation of epidermal placode cells into hair 
germs expanding and differentiating inward into the dermis, finishing when the 
now-recognizable hair follicle has elongated to its full extent down to the 
subcutaneous muscle and organized itself into component structures and cell-
layers 81-83.  
 Following morphogenesis, hair follicles do not retain a static structure 
throughout life but instead proceed to involute and then regrow cyclically. Periods 
of hair follicle retreat (catagen), driven by apoptosis and characterized by the 
regression of the lower portion of the hair follicle, are followed by “resting” 
intervals (telogen) when hair follicles are at their smallest and shortest and are 
largely quiescent 82, 84, 85. Hair follicles then enter a period of rapid cellular 
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proliferation (anagen) where they regrow the lower portion of the follicle and the 
hair shaft, before repeating the cycle all over again. 
 The cyclical replacement during anagen of the cells lost during catagen is 
made possible by adult tissue stem cells resident in the hair follicle. Specifically, 
these stem cells reside in the hair follicle “bulge,” a portion of the basal epithelial 
layer of the follicle (known as the outer root sheath) and the lowermost 
permanently retained portion of the cycling hair follicle 84, 86. Originally identified 
as harboring label-retaining cells and for its ability to regenerate hair follicles after 
transplant 87-89, the hair follicle bulge is marked by expression of keratin 15 (K15), 
as well as by CD34 and a marker of intestinal stem cells, Lrg5 90-93. Activation of 
these slow-cycling hair follicle bulge stem cells is responsible for the generation 
of the transit amplifying cells that regrow the lower portion of the anagen hair 
follicle 86, 89, 94-96. 
  
The Hedgehog (Hh) pathway and the hair follicle 
 The Hedgehog (Hh) signaling pathway is critically important for hair follicle 
development and maintenance. Hh morphogen is required for normal hair follicle 
morphogenesis, and active Hh signaling is also critically required for hair follicle 
cycling in adult animals. Loss of functional Hh signaling results in an early block 
in follicle morphogenesis. In Shh -/- mice mutant for the relevant Hh ligand in the 
skin, initial epidermal placodes and hair germs form, but all subsequent hair 
follicle morphogenesis is prevented 18, 19. Shh signal is also crucial for follicle 
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regrowth during anagen in the hair cycle. Blockade of Shh signaling stops hair 
follicle regeneration in cycling follicles in adult mice 97, and virally-delivered Shh 
overexpression generates the opposite phenotype, inducing hair follicle regrowth 
98. The regrowing lower portion of anagen follicle shows signs of receiving Hh 
signal, from expression of the Hh downstream targets (and pathway 
components) Gli1 and Ptch1 99. There is even recent evidence of Gli1 expression 
(and thus Hh pathway activity) in telogen hair follicle bulge cells which go on to 
repopulate the hair follicle 100, suggesting a Hh pathway interaction with mostly 
quiescent hair follicle bulge stem cells. 
 
Hh pathway activation and basal cell carcinoma (BCC) 
 Given the prominent role the Hh pathway plays in normal hair follicle 
morphogenesis and maintenance in adult skin, it is a short walk to make to arrive 
at the question of whether Hh is similarly required in the abnormal context of hair 
follicle-derived cancers. Many studies over the last two decades have shown this 
emphatically to be so in the case of the hair follicle-derived cancer basal cell 
carcinoma (BCC). Deriving its name from the resemblance by histology of BCC 
tumor cells to the basal layer cells of the epidermis, BCC in patients most 
commonly presents as a slow-growing nodular skin lesion on the body areas 
receiving heaviest sun exposure 101. Although BCC is the most commonly 
diagnosed human cancer among persons of European ancestry, it almost never 
metastasizes and thus is very rarely fatal 21. 
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 Great progress in understanding the genetic changes causing and 
molecular mechanisms driving BCC came with the discoveries linking BCC to the 
Hh pathway. The connection was first made when the underlying mutation of 
Gorlin syndrome, a genetic disorder conferring a predisposition for developing 
BCC, was mapped to Patched1 (Ptch1), the gene encoding the inhibitory 
receptor for Hh ligands 64-66. From there, it became clear that nearly all sporadic 
human BCC also bore mutations in Hh pathway genes, with 90% of sporadic 
human BCC carrying mutations in the inhibitory receptor gene PTCH1 and 
another 10% bearing mutations in the gene for the Hh signal transducer 
Smoothened (SMO) 21. 
 Mouse models confirmed the importance of Hh pathway aberrant 
activation as the primary causative agent driving BCC formation. In recapitulation 
of the human disease, Ptch1+/- heterogzygous mice carrying one mutant allele of 
Ptch1 develop BCC upon induction with UV or ionizing radiation 102, 103. Activating 
the Hh pathway in the skin works all by itself, without the radiation, as 
demonstrated by the successful generation of BCC-like tumors in mice with 
conditionally targetable Ptch1 alleles 20 or inducible constitutively active Smo 
alleles 104.  
 Analogous to its periodic requirement for maintenance of normal hair 
follicle through cycles of anagen regrowth, sustained Hh pathway activity is also 
required for the maintenance of BCC in mouse skin 22. In an additional parallel to 
normal hair follicle development, a long-suspected location for the BCC cells-of-
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origin is the same locale in which the follicle stem cells that regrow cycling hair 
follicles reside, namely the hair follicle bulge. Lineage-tracing using a bulge 
specific marker, coupled with radiation-induced BCC formation in Ptch1+/- skin, 
points towards hair follicle bulge stem cells as the BCC cell-of-origin 8. However, 
a recent publication from Youssef et al. (2010) has questioned the bulge as the 
location of BCC cells-of-origin. Using an in vivo model of BCC generated by 
expression of an activated Smo allele, their results pointed instead towards 
progenitor cells residing in the interfollicular epidermis 9. 
 
The role of Zfx in Hh-dependent BCC in the skin 
 The zinc-finger transcription factor Zfx is absolutely required for the self-
renewal of two highly disparate stem cell types, embryonic stem cells (ESC) and 
murine adult hematopoietic stem cells (HSC) 74, 75. The role of Zfx in the context 
of cancer models, however, remains controversial. In this Chapter, we asked 
whether Zfx was required in the context of Hh-dependent BCC. To answer this 
question, we employed mouse models that would make BCC by deleting 
inhibitory Ptch1 or expressing constitutively active Smo, while at the same time 
also deleting Zfx. We found that Zfx loss prevented BCC formation in the skin 
after Hh pathway overactivation due to Ptch1 loss or activated Smo expression. 
Together, these results identify Zfx as a novel transcription factor required cell-
intrinsically for the development of Hh-dependent BCC. 
 




Establishing a tamoxifen-inducible system for co-deleting Ptch1 and Zfx and for 
BCC generation in vivo 
 We began by asking whether Zfx was required for the initiation and 
progression of BCC triggered by Hedgehog pathway activation in vivo. To 
establish a system where we could answer this question, we first obtained mice 
bearing a “floxed”, excisable allele of Patched1 (Ptch1flox) 105, the gene encoding 
the Hh pathway inhibitory receptor. We crossed these animals to mice carrying a 
transgene encoding a tamoxifen (Tmx)-inducible allele of Cre recombinase under 
the control of the ubiquitous Rosa26 promoter (R26-CreER), along with either 
wild-type (ZfxWT) or targetable (Zfxflox) 74 alleles of Zfx. By crossing together 
resultant progeny, we established two independent breeding lines where 
administration of tamoxifen could effect either deletion of Ptch1 alone (Ptch1flox 
R26-CreER+)(Fig. 2A) or deletion of both Ptch1 and Zfx (Ptch1flox Zfxflox/Y R26-
CreER+)(Fig. 2B). 
 
Topical tamoxifen successfully deletes Zfx from epidermis and hair follicles in 
treated dorsal skin 
 Before investigating the effects of Zfx deletion on BCC initiation and 
progression, we first asked whether administration of tamoxifen to the skin of 
Ptch1flox R26-CreER+ and Ptch1flox Zfxflox R26-CreER+ mice could successfully 
   
22 
ablate targetable alleles from cells in the basal layer of the interfollicular 
epidermis and in the hair follicle. We shaved dorsal skin of male Ptch1flox R26-
CreER+ mice (designated as Ptch1 in Figures), Ptch1flox Zfxflox R26-CreER+ mice 
(Ptch1 Zfx), and CreER- (Ctrl) littermates and treated it with topical tamoxifen for 
five consecutive days to enforce deletion. To help ensure that topical tamoxifen 
infiltrated down through the entire hair follicle, mice were shaved in age-matched 
cohorts at 7-8 weeks of age, aiming temporally for the second telogen of their 
hair cycle 85 when most hair follicles should be quiescent and synchronized at 
their shortest length.  
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Figure 2. Generation of Tmx-inducible 23elete mice for Ptch1 and Zfx 
Mice homozygous for conditionally targetable “floxed” alleles of Patched1 
(Ptch1flox) were bred to mice bearing the Rosa26-CreERT2 transgene (R26-
CreER), expressing a tamoxifen (Tmx)-inducible Cre recombinase under the 
control of a ubiquitous promoter, and either wild-type (ZfxWT) or targetable (Zfxflox) 
alleles of Zfx. Shown are schematics depicting the breedings to generate 
separate mouse lines for Tmx-induced deletion of Ptch1 alone (A) or co-deletion 
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We subsequently analyzed dorsal skin patches from treated mice 3 days 
after the termination of tamoxifen treatment, by both immunohistochemistry (IHC) 
and by qPCR on RNA from bulk epidermis and hair follicles (Fig. 3). In IHC 
sections from Tmx-treated dorsal skin from Ctrl mice, nuclear staining for Zfx 
protein can be observed in cells throughout the basal layer of the epidermis and 
down into the hair follicle (Fig. 4A). In contrast, IHC staining for Zfx in sections 
from Tmx-treated Ptch1 Zfx skin showed the loss of strong nuclear Zfx staining in 
many (but not all) cells in the epidermis and follicle, including cells in the stem 
cell-containing hair follicle bulge (Fig. 4B). These data suggest that the applied 
topical tamoxifen is successfully reaching cells throughout the epidermis and hair 
follicle of treated mice, to activate CreER-mediated excision and delete targetable 
“floxed” alleles. 
Additional evidence for successful Tmx-mediated deletion came from gene 
expression analysis of the treated skin patches. Cohorts of Ptch1, Ptch1 Zfx, and 
CreER- (Ctrl) mice were sacrificed 3 days after Tmx treatment, and bulk 
epidermis and hair follicles from the treated dorsal skin patch were isolated and 
processed for RNA isolation and for subsequent gene expression analysis by 
qPCR. Levels of Zfx mRNA were comparable between Ptch1 and Ctrl samples 
but were decreased nearly 10-fold in samples from Ptch1 Zfx mice carrying the 
targetable allele of Zfx (Fig. 4C). Tmx-treated Ptch1 Zfx skin also showed 
decreased expression of Dis3L, a previously validated transcriptional target of Zfx 
across multiple cell-types 74-76. Combined with the decreased nuclear Zfx 







Figure 3. Topical Tmx treatments for BCC induction in vivo 
Male singly-deleting Ptch1flox/flox ZfxWT/Y R26-CreER+ and doubly-deleting 
Ptch1flox/flox Zfxflox/Y R26-CreER+ mice were shaved across their dorsal skin at 7-9 
weeks of age and treated with tamoxifen (Tmx) to induce deletion of Ptch1 in the 
skin, with or without Zfx co-deletion. Shown is a schematic diagram illustrating 
the treatment regimen of 5 consecutive doses of daily 1 mg tamoxifen, topically 
applied to shaved dorsal skin, before analysis of treated skin three days (3d) or 
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Figure 4. Topical Tmx successfully ablates Zfx in treated dorsal skin 
As described in Figure 2, Ptch1flox/flox Zfx+/y R26-CreER+ (Ptch1) and Ptch1flox/flox 
Zfxflox/y R26-CreER+ (Ptch1 Zfx) mice, along with Ptch1flox/flox R26-CreER- controls 
(Ctrl), were treated topically with tamoxifen (Tmx) to induce deletion of Ptch1 
alone or of both Ptch1 and Zfx in the skin.  
(A&B) Shown is Zfx expression in the skin 3 days after Tmx treatment. 
Representative micrographs of IHC staining for Zfx in sections from treated Ctrl 
(A) and Ptch1 Zfx (B) dorsal skin are shown. Scale bars represent 100 µm (upper 
panel) and 50 µm (lower panel). Epidermis (E), dermis (D), and hair follicle (F) 
are labeled, and the boundary between epidermis/follicles and dermis is marked 
(dotted line; upper panel). Zoomed insets show decreased nuclear staining for 
Zfx in the follicle (lower panel). 
(C) Expression levels of Zfx and the Zfx target gene Dis3L in bulk epidermis and 
hair follicles from shaved dorsal skin 3 days after topical Tmx treatment in Ptch1, 
Ptch1 Zfx, and CreER- (Ctrl) mice. Shown are normalized expression levels 
relative to Ctrl skin as determined by qPCR (mean ± SD of 2-4 mice; 
representative of four independent experiments). 
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detected after Tmx treatment by IHC, these qPCR data showing decreased Zfx 
expression confirm that our topical tamoxifen application successfully deletes 
targetable alleles in shaved, treated dorsal skin. 
 
Co-deletion of Zfx prevents BCC development after Ptch1 deletion in vivo 
 After the demonstration from IHC and qPCR data that topical tamoxifen 
could successfully delete targeted alleles in the interfollicular epidermis and hair 
follicle, we asked two further questions as logical follow-ups. First, we needed to 
confirm that topical Tmx administration and resultant deletion of Ptch1 in treated 
skin would generate BCC in vivo in our hands. Second, if the expected BCC after 
Tmx was observed, we sought to determine whether co-deletion of Zfx in treated 
skin would impair or prevent BCC development. 
 To answer these questions, we followed cohorts of shaved male mice as 
they aged after induction of Ptch1 and Zfx deletion, observing them until 8-9 
weeks after Tmx application. During this time period, Ptch1flox/flox ZfxWT/Y R26-
CreER- (Ctrl) mice re-grew hair throughout the treated dorsal skin patch (Fig. 5A). 
In stark contrast, Ptch1 mice, which deleted only Ptch1 after Tmx, lost the hair on 
and developed gross induration of the skin over most of their treated dorsal skin 
(Fig. 5A). Then, looking at the mice that would co-delete Zfx, we observed that 
Ptch1 Zfx mice largely retained regrown hair and intact skin in the Tmx-treated 
dorsal skin patch (Fig. 5A), akin to what we saw with the Ctrl mice. 
  















Ptch1 Zfx! P = 0.0001!
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Figure 5. Co-deletion of Zfx prevents BCC development after Ptch1 
deletion in vivo 
Mice carrying tamoxifen (Tmx)-inducible Cre recombinase and conditional alleles 
of Ptch1 alone (Ptch1) or of both Ptch1 and Zfx (Ptch1 Zfx), as well as R26-
CreER- ZfxWT littermate controls (Ctrl), were treated with Tmx on shaved dorsal 
skin, as described in Figure 3. 
(A) Representative photographs showing dorsal skin of mice of the indicated 
genotypes following euthanasia 8 weeks after Tmx treatment. 
(B) BCC development in the mice of indicated genotypes. Shown are sections of 
dorsal skin isolated 8 weeks after Tmx treatment and stained with H&E. Scale 
bars represent 100 µm. 
(C) Pathology scores of BCC in treated skin 8-9 weeks after Tmx treatment. 
Shown are the fractions of indicated BCC severity scores in Ctrl, Ptch1 and 
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 Next, we looked more closely at treated skin 8-9 weeks after Tmx via 
histology. Histological analysis of paraffin sections from skin of Ptch1 mice at 8 
weeks post-Tmx revealed frank BCC throughout the tissue sections, with 
massive dermal infiltration and multiple dermal cysts in lieu of the intact hair 
follicle (Fig. 5B). Ptch1 Zfx skin, on the other hand, showed only occasional 
aberrant follicles or instances of potential incipient BCC (Fig. 5B) and otherwise 
more closely resembled the wild-type follicles and epidermis seen in CreER- 
(Ctrl) tissue sections. 
 The differences in BCC development we observed by eye and by 
histology between Ptch1 and Ptch1 Zfx mice were further supported by pathology 
scoring of histological sections. Blinded scoring of hematoxylin and eosin (H&E) 
stained sections from treated dorsal skin 8-9 weeks after tamoxifen confirmed 
that Ptch1 Zfx mice exhibited significantly reduced pathology scores for BCC 
when compared with Ptch1 mice (Fig. 5C). The great majority of the Ptch1 Zfx 
sections scored (11/13) received the lowest score above wild-type baseline. 
Meanwhile, on the side of our positive control in this BCC model, the majority of 
the Ptch1 sections (5/9) received the highest pathology score, a score received 
by none of the Ptch1 Zfx sections (Fig. 5C). Combined with the difference in BCC 
phenotypes observed by eye and in histological sections for Ptch1 and Ptch1 Zfx 
skin, these data strongly suggested that Zfx co-deletion severely impairs or 
prevents BCC following Ptch1 inactivation in vivo. 
  




Figure 6. Zfxnull BCC do not develop following Ptch1 deletion in the skin  
As described in Figure 5, mice were shaved across their dorsal skin at 7-9 weeks 
of age and were treated with topical Tmx to enforce deletion and induce BCC. 
Shown are representative micrographs of Ptch1flox/flox R26-CreER- (Ctrl), 
Ptch1flox/flox ZfxWT/y R26-CreER+ (Ptch1), and Ptch1flox/flox Zfxflox/y R26-CreER+ 
(Ptch1 Zfx) dorsal skin sections isolated 8-9 weeks after Tmx and stained with 
antibodies against Sox9 (A) or Zfx (B). Sections are counterstained with 
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Zfxnull BCC does not form and Zfxnull hair follicles are not maintained in skin after 
Tmx-induced deletion  
 We examined sections from 8-9 weeks post-Tmx skin patches by IHC, to 
confirm that BCC we generated with Tmx-induced Ptch1 and Zfx deletion bore 
biochemical markers of BCC. We stained slides with antibody raised against 
Sox9, a marker of the hair follicle stem cell compartment and outer root sheath 
that also marks BCC tumors 106. BCC in sections from Ptch1 skin stained 
positively for Sox9 (Fig. 6A), as did hair follicles in skin from R26-CreER – (Ctrl) 
and Ptch1 Zfx mice (Fig. 6A). Sox9+ staining in the tumors supports the 
conclusion that we have successfully generated model BCC in vivo using Ptch1 
deletion, as intended. 
 We also wanted to examine the expression of Zfx protein in skin sections 
8-9 weeks after Tmx-induced deletion. After staining slides with anti-Zfx antibody, 
we noted nuclear Zfx staining throughout the basal layer of the epidermis and 
hair follicle in Ctrl skin (Fig. 6B), as we had also observed previously in skin 3 
days post-Tmx treatment. Cells in BCC in skin sections from Ptch1 mice also 
stained positive for nuclear Zfx (Fig. 6B). Interestingly, however, most cells in the 
epidermis and in normal and abnormal hair follicles from Ptch1 Zfx skin 8-9 
weeks post-Tmx also stained positively for nuclear Zfx (Fig. 6B). This unexpected 
result contrasted with the Zfx deletion we previously observed by IHC in Ptch1 
Zfx skin 3 days post-Tmx (Fig. 4B). The absence of Zfxnull hair follicles or incipient 
BCC in Ptch1 Zfx skin 8-9 weeks post-Tmx suggests that there is strong 
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selection favoring Zfx non-deleter cells in the skin following Tmx-induced gene 
ablation. These data also strengthened the conclusion from histology and 
pathologist scoring of Ptch1 Zfx skin (namely, that Zfx co-deletion severely 
impairs or prevents BCC development), showing that any abnormal follicles or 
incipient BCC which eventually develop in Ptch1 Zfx skin are comprised of cells 
that fail to delete Zfx. 
 
Zfx loss decreases expression of the Hh pathway signal transducer Smo and 
blunts Hh pathway activation after Ptch1 deletion in the skin 
 Because evidence so far suggested that loss of Zfx prevented BCC 
initiation in the skin after Hh pathway activation due to Ptch1 deletion, we asked 
whether we could detect changes in the expression of any of the core 
components or direct targets of the Hh signaling pathway after Zfx co-deletion. 
To answer this question, we again utilized the cohorts of Ptch1, Ptch1 Zfx, and 
CreER – (Ctrl) mice that we sacrificed 3 days after Tmx, for RNA extraction from 
bulk epidermis/hair follicles of dorsal skin and subsequent gene expression 
analysis by qPCR. Notably, Smo transcript levels were decreased by 
approximately 2-fold in Ptch1 Zfx samples, compared to Ptch1 and Ctrl skin (Fig. 
7), correlating with decreased Zfx levels in Ptch1 Zfx skin. Additionally, in skin 
from Ptch1 mice, expression levels of the Hh pathway targets Gli1 and Mycn 
were substantially increased (Fig. 7), consistent with an activation of the Hh 
pathway following deletion of the inhibitory Ptch1. In contrast, in Ptch1 Zfx mice 
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this increase in Gli1 and Mycn expression was blunted nearly down to the levels 





Figure 7. Loss of Zfx correlates with decreased Smo expression and 
blunted overexpression of Hh pathway target genes after Ptch1 deletion in 
the skin 
Expression levels of Zfx, Smo, and Hh pathway target genes in bulk epidermis 
and hair follicles from shaved dorsal skin 3 days after topical Tmx treatment in 
Ptch1, Ptch1 Zfx, and Ctrl mice (as described in Figure 5). Shown are normalized 
expression levels relative to Ctrl skin as determined by qPCR (mean ± SD of 2-4 
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blunted overexpression of Hh targets Gli1 and Mycn after Zfx co-deletion suggest 
a simple hypothetical explanation of the observed prevention of Hh-dependent 
BCC formation after Zfx loss. Specifically, the transcription factor Zfx could 
regulate the expression of Smo in the skin, and therefore be required for Hh 
pathway activation after Ptch1 loss in this in vivo model of BCC. 
 
Loss of Zfx impairs BCC formation caused by an activated Smo allele 
“downstream” of endogenous Smo 
 We then attempted some preliminary experiments, to test this new 
hypothetical explanation for Zfx requirement in BCC formation after Ptch1 
deletion. We reasoned that: if transcriptional regulation of Smo alone explains the 
loss-of-Zfx phenotypes in Hh-dependent BCC, then BCC models initiated by Hh 
pathway activation downstream of Smo should be immune to effects from Zfx 
deletion. To investigate this possibility, we obtained transgenic Rosa26-
SmoM2stop-flox-stop-EYFP (R26-SmoM2) mice 104. The SmoM2 allele, a missense 
mutant allele mimicking a human SMO missense mutant identified from BCC 
patients, encodes a constitutively active Smo that generates BCC in mice 104, 107. 
R26-SmoM2 mice will express this Smo allele, fused with enhanced yellow 
fluorescent protein (EYFP), from the ubiquitously-expressed Rosa26 promoter, 
but only after Cre-mediated excision of a loxP-flanked “stop” cassette 104. 
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Figure 8. Generation of Tmx-inducible SmoM2 mice for initiating BCC using 
a constitutively active Smo allele 
Mice homozygous for inducible “stop-floxed” transgene encoding a constitutively 
active allele of Smo (R26-SmoM2) were crossed with Tmx-inducible R26-CreER 
mice that had either wild-type (ZfxWT) or conditional (Zfxflox) alleles of Zfx.  
(A&B) Shown are schematics depicting the breedings to generate experimental 
male mice for Tmx-induced excision of the “stop-flox” cassette and expression of 
the constitutively active SmoM2 allele, with concomitant retention of ZfxWT (A) or 
deletion of Zfxflox (B) alleles. 
(C) Schematic diagram illustrating the treatment regimen of 5 consecutive doses 
of daily Tmx (1 mg), topically applied to shaved dorsal skin, before analysis of 
treated skin 3 days after Tmx by qPCR, or 5-6 or 8-10 weeks after Tmx by IHC.  
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Figure 9. Zfx co-deletion impairs BCC progression after SmoM2 expression 
and Hh pathway activation downstream of endogenous Smo 
Mice carrying tamoxifen (Tmx)-inducible Cre recombinase and an inducible 
“stop-floxed” transgene encoding the constitutively active R26-SmoM2 allele,  
with (SmoM2 Zfx) or without a conditional allele of Zfx, were treated with Tmx on 
shaved dorsal skin, as described in Figure 8. 
(A) Representative photographs showing dorsal skin of mice of the indicated 
genotypes following euthanasia 8-10 weeks after Tmx treatment. 
(B&C) BCC formation in treated dorsal skin after SmoM2 induction. Shown are 
representative micrographs of sections of dorsal skin isolated 8-10 weeks after 
Tmx treatment from SmoM2 Zfx and SmoM2 mice, then stained with H&E (B) or 
with anti-Zfx antibody (C). Scale bars represent 100 µm. 
(D) Pathology scores in treated skin after Tmx treatment to inititate SmoM2-
dependent BCC induction. Shown are the fractions of indicated BCC severity 
scores in SmoM2 and SmoM2 Zfx mice, with Ptch1flox/flox ZfxWT/Y R26-CreER- 
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 We bred homozygous R26-SmoM2 mice with homozygous Rosa26-
CreERT2 (R26-CreER) mice carrying wild-type or conditional alleles of Zfx (Fig. 
8A,B). Resulting double-heterozygote R26-CreER+ R26-SmoM2+ ZfxWT/Y 
(designated SmoM2)(Fig. 8A) and R26-CreER+ R26-SmoM2+ Zfxflox/Y (designated 
SmoM2 Zfx)(Fig. 8B) males were shaved along their dorsal skin and treated 
topically with Tmx to induce BCC formation, as had been done previously with 
Ptch1 conditional mice (Fig. 8C). In this case, a small subset of the SmoM2 and 
SmoM2 Zfx mice were shaved and painted with Tmx at 3-4 weeks of age during 
the presumptive 1st telogen of their hair cycle 85, to attempt to induce BCC on a 
shortened time scale (Fig. 8C). 
 The effects we observed previously in the Ptch1-dependent BCC model, 
such as hair loss and gross induration over the treated skin patch, were slower to 
develop and appeared less severe in the R26-SmoM2 BCC mice. However, by 8-
10 weeks post-Tmx (or 5-6 weeks in the younger Tmx-treated mice), hair loss 
and sclerotic hardening of the skin in Tmx-treated dorsal skin patch was 
observed in SmoM2 mice but not in SmoM2 Zfx mice (Fig. 9A). 
BCC-like tumors could be observed in H&E sections from SmoM2 treated dorsal 
skin, where SmoM2 Zfx skin had hair follicles closer to wild-type in appearance 
(Fig. 9B). Similar to the case in Ptch1 Zfx mice, co-deletion of Zfx was not 
maintained over time in SmoM2 Zfx mice. Anti-Zfx staining of SmoM2 Zfx skin 
sections did not reveal Zfxnull follicles, normal or aberrant, and Zfx nuclear 
staining was detected throughout the epidermis in both SmoM2 and SmoM2 Zfx 
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dorsal skin (Fig. 9C). Furthermore, although the sample sizes were very small, 
pathologist scoring of SmoM2 and SmoM2 Zfx skin sections from 8-10 (or 5-6) 
weeks post-Tmx showed a significantly decreased severity in disease score for 
SmoM2 Zfx mice compared to SmoM2 mice (Fig. 9D). Collectively, these results 
from the R26-SmoM2 model of BCC resemble the results from the Ptch1 model, 
and they suggest that Zfx co-deletion also strongly impairs BCC generated by 
constitutively active SmoM2 “downstream” of endogenous Smo. 
 Conversely, preliminary results from qPCR-based gene expression 
analysis of treated skin in a single cohort of R26-SmoM2 mice are quite different 
from those seen previously with the Ptch1 model (Fig. 10). Decreased expression 
levels for Zfx (~8 to 10-fold) and the Zfx target Dis3L (~2-fold) in SmoM2 Zfx skin 
3 days after Tmx do match the results from the Ptch1 conditional system, as well 
as confirm the successful co-deletion of Zfx by Tmx application. However, qPCR 
results for the Hh signal transducer Smo and Hh target Gli1 are strikingly different 
than we saw previously. Smo levels are not reduced after Zfx deletion, and 
increased Gli1 expression is not blunted after the loss of Zfx (Fig. 10). These 
expression data suggest that impairment in SmoM2-dependent BCC 
development due to Zfx co-deletion is not mediated through transcriptional 









Figure 10. Loss of Zfx does not cause decreased expression of Smo or Hh 
target Gli1 after Tmx-induced SmoM2 expression in the skin 
Expression levels of Zfx, the Zfx target Dis3L, Smo, and Hh pathway target gene 
Gli1 in bulk epidermis and hair follicles from shaved dorsal skin 3 days after 
topical Tmx treatment in SmoM2 (n= 5), SmoM2 Zfx (n= 3), and R26-CreER- 
Ptch1flox (Ctrl) (n= 2) mice. Shown are normalized expression levels relative to 
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Discussion 
 We asked whether the transcription factor Zfx was required for 
tumorigenesis in the Hh-dependent skin cancer basal cell carcinoma. Given the 
cell-intrinsic requirement for Zfx in the self-renewal of murine HSC and ESC 74, 75, 
we hypothesized that Zfx might also be required in the context of this Hh-
dependent cancer, especially considering that BCC is thought to arise from the 
stem cell and progenitor compartment in the hair follicle bulge 8. Here, we 
demonstrated that formation of Hh-driven BCC was severely impaired or 
prevented in dorsal skin of Ptch1 Zfx (Fig. 5) and SmoM2 Zfx mice (Fig. 9), 8-10 
weeks after topical Tmx treatment induced Zfx co-deletion and Hh pathway 
activation via removal of inhibitory Ptch1 or introduction of activated Smo, 
respectively. Zfxnull BCC were not detected in either the Ptch1-dependent (Fig. 6) 
or SmoM2-dependent (Fig. 9) mouse models.  These results demonstrated a 
cell-intrinsic requirement for Zfx in the development of the Hh-driven cancer BCC. 
 A number of established therapies exist for treating BCC, including several 
forms of surgical excision, radiation treatment, and topical imiquimod or 5-
fluorouracil (5-FU) application 108, 109. While these established therapies have the 
upside of high effective clearance rates, often approaching 100%, they also have 
some drawbacks. Surgical excision can leave behind residual tissue damage, 
and topical imiquimod or 5-FU therapies are only recommended for superficial 
BCC 108, 109. The discoveries of the mid- and late-1990s linking BCC to mutations 
in PTCH1 or SMO 21, 65, 66 paved the way for the addition of a new tool to this 
   
45 
armamentarium: small molecule inhibitors targeting the Hh pathway. Phase I 
clinical trials of inhibitors targeting the Hh signal transducer, SMO, have shown 
promising results in treating patients with advanced or metastatic BCC 110. Since 
Zfx is required for BCC to develop in vivo, one future possibility is that Zfx or its 
relevant downstream transcriptional targets could represent novel druggable 
molecules for treatment of BCC. 
 Our preliminary investigations into downstream Zfx targets with functional 
relevance in BCC pointed towards Smo. After inducing Ptch1 deletion and Hh 
pathway activation with topical Tmx, Ptch1 Zfx mice (which co-delete Zfx) had 
decreased Smo expression in treated skin, and the overactivation of Hh pathway 
as gauged by Gli1 and Mycn expression was prevented (Fig. 7). These data 
favored a simple explanation of the role of Zfx in Hh-dependent BCC: Zfx is 
necessary for Smo expression after removal of Ptch1, and loss of Zfx thus 
decreases the levels of the Hh pathway signal transducer, blocking the pathway 
overactivation that initiates BCC. Such an explanation is consistent with previous 
work in mouse models to generate BCC, whence we know that Hh activation via 
ablation of Ptch1 is sufficient to successfully generate BCC 20 and that sustained 
Hh pathway activation is required to maintain them 22. 
 This first explanation for the role of Zfx in BCC development runs up 
against complications when we consider our experimental results from the 
generation of BCC using activated SmoM2 allele. As with the Ptch1-dependent 
BCC model previously, we found that co-deletion of Zfx significantly impaired 
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BCC development after induction of constitutively active SmoM2 in the skin and 
that Zfxnull BCC or aberrant follicles were not observed (Fig. 9). In the SmoM2-
dependent BCC model, however, Hh pathway activity is driven by expression of a 
constitutively active Smo, “downstream” or at least independently of endogenous 
Smo. Expression analysis in treated SmoM2 Zfx skin showed the same loss of 
Zfx expression as in Ptch1 Zfx skin, but Smo transcript levels were not 
decreased and overexpression of Hh targets Gli1 and MycN were not blunted 
(Fig. 10). Zfx is thus required in BCC initiated by either deletion of inhibitory 
Ptch1 or activated SmoM2 expression, but evidence for Zfx control of Hh 
activation via Smo is present in only the former case. 
 There are at least two possible explanations for this discrepancy. One 
possibility is that Ptch1-dependent and SmoM2-dependent BCC represent two 
tumor cell environments distinct enough that the relevant downstream targets of 
Zfx in the two different models are different. There is precedent in the literature 
suggesting that BCC generated by Ptch1 loss and SmoM2 expression are 
substantially different. A recent study generated BCC in Ptch1+/- mutant mice 
treated with ionizing radiation, mimicking a common etiology of human BCC, and 
subsequently identified cells of hair follicle bulge stem cell compartment as the 
predominant BCC cells-of-origin, using cell fate mapping with inducible Cre 
specific to the bulge (K15-CrePR1) or widely expressed in the epidermis (K14-
CreER) 8. This study from Wang et al. (2011) was a direct response to the 
previous report from Youssef et al. (2010), where the authors generated BCC 
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using inducible Cre transgenes and the same Rosa26-SmoM2 transgene we 
employed in the Results above. In their case, they identified long-lived progenitor 
cells of the interfolliclular epidermis as the BCC cell-of-origin 9. By histology, none 
of the SmoM2 BCC from Youssef et al. (2010) arose from hair follicles, while all 
did in the Ptch1+/- IR model of Wang et al. (2011) 8, 9. These differences between 
BCC models could be explained by ubiquitous expression of SmoM2 by the 
Rosa26 promoter in locales (such as the interfollicular epidermis) where Smo is 
not normally expressed, or by additional non-Hh-specific functions of Ptch1 that 
are lost in Ptch1-deficient BCC but not SmoM2-driven BCC 8. The role of Zfx in 
these two similar but distinct BCC models could be different, with driving of Smo 
expression being crucial in the Ptch1 model but other downstream targets taking 
on significance in BCC generated by Rosa26-driven SmoM2. 
 A second possible explanation for the discrepancy is that the same, yet-to-
be-identified downstream Zfx targets are responsible for the phenotypes in both 
the Ptch1-dependent and SmoM2-driven BCC models. In this case, qPCR results 
for Smo, Gli1, and Mycn from 3 days post-Tmx skin in Ptch1 Zfx mice (Fig. 7) 
would represent a good exampe of correlation not implying causation. Instead, 
Zfx targets such as Dis3L that are downregulated after Zfx co-deletion in both the 
Ptch1-dependent (Fig. 4C) and SmoM2-driven (Fig. 10) models of BCC would be 
the best candidates to explain the prevention of BCC development after Zfx loss. 
 A third and final possible explanation for the discrepancy is that loss of Zfx 
regulation of endogenous Smo expression causes the phenotype in both the 
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Ptch1-dependent and SmoM2-dependent models, but that this loss of 
endogenous Smo is masked in the SmoM2 model by overexpression of the 
transgenic constitutively active Smo allele. Smo has been reported to function as 
a dimer, with phosphorylation of C-terminal Arg clusters and consequent 
dimerization of its C-terminal cytoplasmic tails in response to Hh signal being 
essential for downstream pathway activation 48. In the SmoM2-dependent BCC 
model, it is possible that the overexpressed, constitutively active SmoM2 allele 
still requires endogenous Smo for this dimerization and Hh pathway downstream 
activation. If this were the case, then decreased expression of endogenous Smo 
following Zfx loss would explain the prevention of BCC formation in SmoM2-
dependent BCC, as well as in Ptch1-dependent. Currently, we are unable to 
directly confirm that Zfx co-deletion decreases expression levels of endogenous 
Smo in SmoM2 BCC mice, however, since our qPCR primers detect both 
wildtype transcript and the transcript from the SmoM2 cDNA. Any lowered levels 
of endogenous Smo are therefore masked by the abundant levels expressed off 
the SmoM2 transgene. 
 In this Chapter, we demonstrated a requirement for the transcription factor 
Zfx in the Hh-dependent, hair follicle-derived cancer basal cell carcinoma. The 
downstream targets of Zfx responsible remain unclear, although the Hh signal 
transducer Smo emerged as candidate. In Chapter II, we examine whether a 
requirement for Zfx is generalizable across cancers driven by aberrant Hh 
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pathway activation in progenitor compartments, by examining whether Zfx is 
necessary for development of the cerebellar tumor medulloblastoma (MB). 
  
Materials & Methods 
Animals 
Mice with conditional alleles of the Hh pathway inhibitory receptor gene 
Patched1 (Ptch1flox)105 and of the transcription factor Zfx (Zfxflox)74 have been 
previously described. Tamoxifen (Tmx)-inducible Rosa26-CreERT2 deleter mice 
(R26-CreER+) were kindly provided by Dr. Thomas Ludwig, Columbia 
University74. Homozygous Ptch1flox/flox mice were mated separately with R26-
CreER+ ZfxWT and R26-CreER+ Zfxflox mice to ultimately generate distinct singly-
deleting R26-CreER+ Ptch1flox ZfxWT and doubly-deleting R26-CreER+ Ptch1flox 
Zfxflox breeding lines. Male mice with genotypes R26-CreER+ Ptch1flox/flox ZfxWT/Y 
(designated Ptch1 in Figures) and R26-CreER+ Ptch1flox/flox Zfxflox/Y (designated 
Ptch1 Zfx in Figures) were compared in Tmx-painting and BCC induction 
experiments, with R26-CreER- Ptch1flox/flox ZfxWT/Y littermates (designated Ctrl in 
Figures) serving as negative controls.  
Rosa26-SmoM2 (R26-SmoM2) transgenic mice were obtained from 
Jackson Laboratories. After Cre-mediated excision of a “stop-flox” cassette, 
these mice will express an enhanced YFP-tagged, constitutively active allele of 
Smo under the control of the ubiquitous Rosa26 promoter, and the SmoM2 allele 
has been demonstrated previously to initiate BCC-type tumors in mice in vivo 104, 
107, 111.  Homozygous R26-SmoM2+/+ mice were bred with either R26-CreER+/+ or 
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R26-CreER+/+ Zfxflox/flox mice to generate R26-CreER+ R26-SmoM2+ and R26-
CreER+ R26-SmoM2+ Zfxflox/Y males, respectively, for experiments involving Tmx-
induced of BCC initiation in dorsal skin via activation of the Hh pathway 
downstream (or independently) of endogenous Smo.  
All animal studies were performed according to the investigator’s protocol 
approved by the Institutional Animal Care and Use Committee of Columbia 
University. 
 
RNA Isolation and qPCR 
Total cellular RNA was isolated from samples in 0.5-1 mL TriZol LS reagent 
(Invitrogen).  cDNA was synthesized from 1-2 µg RNA per sample using 
SuperScript III reverse transcriptase (invitrogen). Quantitative real-time PCR 
(qPCR) assaying for SYBR Green incorporation were run on an Mx3000P 
instrument (Stratagene) using FastStart Universal SYBR Green Master mix 
containing Rox (Roche). Triplicate reactions were run for each sample, and 
replicates with a Ct value >1 Ct from any of the other two replicates (while those 
two replicates remained within 1 Ct value of one another) was excluded as an 
outlier. All qPCR results were analyzed using the ΔΔCt method as previously74. 
The expression values for all genes were scaled to total RNA content using Ct for 
the housekeeping genes β-Actin (Actb), β2-microglobulin (B2m), hypoxanthine 
guanine phosphoribosyl transferase (HPRT), or GAPDH, and then normalized to 
the indicated control samples. The qPCR primers are listed below. 
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Species Gene Forward Reverse 
Mouse Actb ATCCTGACCCTGAAGTACC TACGACCAGAGGCATACAG 
 B2m ACCCTGGTCTTTCTGGTGCTTG TATGTTCGGCTTCCCATTCTCC 
 HPRT GCCCCAAAATGGTTAAGGTTGC TCAAGGGCATATCCAACAACAAAC 
 GAPDH AAGGTCGGTGTGAACGGATTTG CTCGCTCCTGGAAGATGGTGAT 
 Zfx GCAGTGCATGAACAGCAAGT GCAAGGTGTTCAGGATGGTT 
 Dis3L AGGGGGAAGCCATGGAGAAG GATTTGATGCCCGCTTCCAG 
 Ube2j1 GACGCATAGTACTGCCACCA ATGGCCCCCTCTCCTTTAGT 
 Smo CTCGGACTCGCAGGAGGAAG TCAGGGAAGTGGTCCGGTGT 
 Gli1 CATTGGGGAGGTTGCTCCAG CCGAAGGTGCGTCTTGAGGT 
 Mycn GGAGAGGATACCTTGAGCGACTC CGCCTTGTTGTTAGAGGAGGAAC 
 Mnx1 AGGCGCAGTCGAACCTCTTG TCCATTTCATTCGGCGGTTC 
 Isl1 CAAGCGGTGCAAGGACAAGA CAGGGCGGCTGGTAACTTTG 
 Olig2 CACCTCCTCGTCCACGTCCT GGCGATCTTGGAGAGCTTGC 
 Tubb3 GGCCATTCTGGTGGACTTGG GCCCTGCAGGCAGTCACAAT 
Human GAPDH AAGGTGAAGGTCGGAGTCAACG CCCACTTGATTTTGGAGGGATC 
 Zfx GCAGGATGATGACAAAGGCAAC CAAGGATCAATTTCCGACTCTGTG 
 Dis3L CCAGGACAGGATGCCAATTGTT CGTGGGCAGCTTTTAAATCAGG 
 Ube2j1 GAAACTTGGCAGCCTTCGTG ATGGCAGAGCCACATCCTTC 
 Smo GCTCATCGTGGGAGGCTACTTC AGCATGGTCTCGTTGATCTTGC 
 Gli1 CTCGGGCACCATCCATTTCTAC GCCAGTCATTTCCACACCACTG 
 
Tamoxifen Treatment of Dorsal Skin 
Adult male mice of the designated genotypes were shaved across their dorsal 
skin at 7-9 weeks of age (with the great majority shaved at postnatal day 50 or 
P50), temporally situating tamoxifen (Tmx) treatment within the second telogen of 
the hair cycle85. Animals were then treated for five consecutive days topically with 
100 µL per day of 10 mg/mL tamoxifen (Sigma) in acetone (i.e. – 1 mg tamoxifen 
q.d.). In the case of experiments with mice bearing the SmoM2 “stop-flox” allele 
of Smo, some mice were shaved instead during their first telogen at 
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approximately 3-4 weeks of age (e.g.- P21 or P22), in an attempt to accelerate 
initiation of BCC. 
For gene expression analysis in bulk epidermis and hair follicles, Tmx-
treated mice were sacrificed three days after final Tmx treatment. Tmx-treated 
dorsal skin was removed, and connective/adipose/vascular tissue was stripped 
from the dermis in cold PBS (Gibco). The remaining dermis and epidermis were 
floated in 0.25% trypsin - 1x EDTA (Gibco), with epidermis/hair follicles up, at 
37°C, 7.5% CO2 for 2 hours, and bulk hair follicles and epidermis were separated 
from dermis into DMEM with 10% FBS using sterile disposable scalpels. Bulk 
follicles/epidermis were minced, collected by centrifugation, and lysed in 2 mL 
TriZol LS reagent (Invitrogen).  
For histological analysis, at 8-9 weeks after Tmx-treatment, mice were re-
shaved if dorsal hair had regrown, and the Tmx-treated patch was removed, 
flattened, and fixed before processing for histology. Again, some exceptions to 
this time-scale occurred in the case of SmoM2+ mice, where mice painted during 
their first telogen (beginning at approximately P21) were instead sacrificed 5-6 
weeks post-Tmx. Additionally, BCC initiation in mice painted during their 
 
Immunohistochemistry 
Dorsal skin from topically Tmx-treated mice was fixed for 24 hrs in zinc formalin 
(Thermo Scientific) and then 24 hours in 70% ethanol. Tissue segments were 
subdissected from the Tmx-treated region, with the long dimension following the 
spinal column midline, and embedded on edge in paraffin. Paraffin sections (5 
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µm) from Tmx-treated skin were stained with hematoxylin and eosin (H&E), or 
were immunostained with anti-Zfx (1:500) or with anti-Sox9 (Santa Cruz, 1:500) 
antibodies, incubated with biotinylated anti-rabbit secondary antibody (Vector 
Labs), visualized ABC and DAB Peroxidase Substrate Kits (Vector Labs), and 
counterstained with hematoxylin. 
Micrographs of histological sections were recorded using an 
AxioImager.M2 microscope with attached AxioCam MRc camera (Zeiss). 
 
Statistics 

















A requirement for Zfx for optimal growth of 
medullblastoma (MB) models in vivo and in vitro 
 
  




Hedgehog (Hh) signaling is required for growth and patterning of the cerebellum 
 The Hedgehog (Hh) family of secreted, intercellular morphogens is critical 
for numerous processes during mammalian development 26. Classic examples of 
Hh function during development include patterning of the distal limb and digits by 
Sonic hedgehog (Shh) secreted from the zone of polarizing activity (ZPA) 112-114, 
or specification of motor neuron (MN) and ventral interneuron progenitor pools in 
the developing spinal cord 55, 115, 116. In Chapter I we touched on another example 
when discussing the requirement for Hh signaling for the original morphogenesis 
and subsequent cycling of the hair follicle 18, 19, 97.  
Shh signaling is also critically important during the development of the 
cerebellum. The cerebellum is a region of the brain most associated with balance 
and sensorimotor function, although it may have additional roles in other 
cognitive functions 117. The different cell types of the cerebellum derive from 
distinct germinal regions. A progenitor domain in the ventricular zone or the IVth 
ventricle gives rise to Purkinje neurons, as well as various cerebellar 
interneurons and glia, while progenitors in the rhombic lip give rise to granule 
neurons, the most numerous neuronal subtype in not only the cerebellum but 
also the entire central nervous system (CNS) 10, 117, 118. Mature granule neurons 
are generated from proliferation of granule neuron precursors (GNP), which 
migrate from the rhombic lip during embryogenesis and form an external granular 
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layer (EGL) on the cerebellar surface 117-119. While there, GNP undergo extensive 
proliferation post-natally (until postnatal day 15 in mice and postnatal year 2 in 
humans), before differentiating into granule neurons and migrating inward to 
constitute an internal granule layer 117-119. Shh signaling is critically required 
during this process. Hh pathway activation, from Shh signal received from 
Purkinje cells, is required for the expansion of GNP in the EGL and for normal 
growth and patterning of the cerebellum 24, 119. The characteristic lobed foliation 
pattern of the cerebellum also depends on the levels of functional Hh signaling 
during development, as demonstrated in mouse models where graded decrease 
in Shh signaling generated increasingly stunted cerebellar foliation 23. 
 
The cerebellar tumor medulloblastoma (MB) is linked to Hh pathway activation 
 In another parallel with the discussion of hair follicles and the follicle-
derived cancer basal cell carcinoma (BCC) from Chapter I, aberrantly activated 
Hh signaling also acts as the etiological agent for a cancer of the cerebellum, 
namely medulloblastoma (MB). Primarily a pediatric cancer, MB is the most 
common malignant brain tumor in infants and children 117, 118. Survival rates for 
MB following conventional therapy with surgery, radiation, and chemotherapy 
approach 70-80%, but surviving patients are consequently subject to an array of 
long-term side effects 67. 
 Genome-wide analyses over the last decade have revealed the name 
“medulloblastoma” to be something of an umbrella term, encompassing four 
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molecularly distinct cancer subtypes 68, 120-123 that originate from different cell-
types and regions of the brain 10-12, 124. These MB subtypes include a WNT 
subtype, a SHH subtype, and two other groups yet to be definitively named, 
although one bears a MYC mutation signature 67. Hh-driven MB account for 
approximately 30% of all MB, carry an intermediate prognosis, cluster primarily in 
infant or in adult patients, and are marked primarily by a desmoplastic/nodular 
histological appearance, although they can less frequently exhibit large cell 
anaplastic or “classic” histology 67, 68. 
 The first connection between the Hh pathway and MB was actually 
established well before its confirmation in these genomics studies, from the same 
studies linking the hereditary condition Gorlin Syndrome to mutations in the 
inhibitory receptor PTCH1 that also linked Hh pathway activation to the skin 
cancer BCC 65, 66. When MB development was observed in mice heterozygous 
for mutant Ptch1 125, 126, or in mice with tissue-specific, Cre-mediated Ptch1 
deletion or constitutively active Smo expression 10, 11, it confirmed Hh pathway 
activation as a driver of MB. Creative use of mouse models also led to 
identification of the cell-of-origin for Hh-dependent MB. Mice deleting Ptch1 or 
expressing activated Smo in neural stem cells, or later in granule neuron 
precursors using the GNP-specific Math1-Cre, revealed that Hh-dependent MB 
arise from GNP in the developing cerebellar EGL 10, 11. Thus, mirroring 
intriguingly the situation with Hh-dependent BCC formation from cells of the hair 
follicle bulge, MB also develops following uncontrolled activation of Hh signaling 
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in a progenitor-bearing compartment of the cerebellum that is sensitive to Hh 
signal during its normal development. 
 
An incomplete requirement for Zfx in Hh-dependent MB 
 In Chapter I, we observed that co-deletion of Zfx prevented the formation 
of BCC in vivo following tamoxifen (Tmx)-induced activation of the Hh pathway in 
the skin. In this Chapter, we asked whether Zfx was similarly required for 
initiation and maintenance of a Hh-dependent MB. Using a previously validated in 
vivo model for generating Hh-dependent MB 11, we established mouse lines that 
initiated MB via nearly CNS-wide deletion of the inhibitory receptor Ptch1, with or 
without concomitant deletion of Zfx. Co-deletion of Zfx significantly delayed, but 
did not prevent, MB growth after Ptch1 deletion. Loss of ZFX also impaired 
growth of human MB cells in vitro. Zfx was not required, however, for 
development in a model of PTEN-dependent glioblastoma, a different brain 
tumor. Combined with our data from BCC models in Chapter I, these models 
suggest that there is a common cell-intrinsic requirement for Zfx shared by two 
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Results 
Establishing a CNS-specific model for co-deleting Ptch1 and Zfx and for Hh-
dependent MB generation in vivo 
  Having previously observed a requirement for Zfx in BCC development 
stemming from Hh pathway activation in the skin, we asked whether Zfx was 
similarly required for the formation and growth of Hh-dependent MB. To answer 
this question, we utilized mouse strains carrying the same conditionally 
targetable “floxed” alleles of Patched1 (Ptch1flox)105 and Zfx (Zfxflox)74 that we 
used previously to generate Hh-dependent BCC in vivo. In the case of MB, since 
the cerebellum does not afford the same ease of access for tissue-targeted 
tamoxifen (Tmx) treatments as the skin, we eschewed the Tmx-inducible but 
ubiquitously expressed Rosa26-CreER and instead obtained the non-inducible 
but CNS-specific hGFAP-Cre. 
 Originally intended to be an astrocyte-specific Cre transgene, hGFAP-Cre 
begins expressing Cre recombinase under the control of the human glial fibrillary 
acid protein (hGFAP) promoter in the developing mouse brain at embryonic day 
13.5 (E13.5), and it instead effects deletion of targeted alleles in nearly all cell 
types in the brain, with the exception of cerebellar Purkinje neurons and cells of 
the choroid plexus 127. Included on the list of CNS cell-types covered by hGFAP-
Cre are the granule neuron precursor (GNP) cells which are the cells-of-origin in 
Hh-dependent MB, and hGFAP-Cre-mediated deletion of Ptch1 has been 
successfully used previously as a system to generate MB in vivo 10, 11.  
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Figure 11. Generation of CNS-specific deleter mice for Ptch1 and Zfx 
Mice bearing the hGFAP-Cre transgene, which expresses Cre recombinase and 
effects deletion in nearly all CNS cell-types, were bred with mice bearing 
conditional alleles of Patched1 (Ptch1flox) and Zfx (Zfxflox) to generate single- or 
double-deleter mice that would develop Hh-dependent medulloblastoma (MB). 
(A) Schematic depicting generation of hGFAP-Cre+ Ptch1flox/WT ZfxWT/Y breeder 
males for the crosses generating Hh-dependent MB mice. 
(B) Generation of positive control hGFAP-Cre+ Ptch1flox/flox ZfxWT mice. Breeder 
males generated in (A) were bred with Ptch1flox/flox ZfxWT/WT Rosa26-CreER – mice 
(Fig. 2A), yielding singly-deleting MB mice and also regenerating breeder males. 
(C) Generation of experimental hGFAP-Cre+ Ptch1flox/flox Zfxflox/Y mice. . Breeder 
males generated in (A) were bred with Ptch1flox/flox Zfxflox/flox Rosa26-CreER – mice 
(Fig. 2B), yielding doubly-deleting experimental MB mice. 
  











Figure 12. Hh-dependent MB induction by Ptch1 deletion in vivo 
Experimental setup for observation of mice that delete Ptch1 with or without Zfx 
co-deletion and that develop Hh-dependent MB. Animals were followed for 
survival curve and sacrificed at defined postnatal days of age (P7, P14, P21) for 
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 To begin to replicate this model of Hh-dependent MB, we obtained 
hGFAP-Cre mice and bred them to Ptch1flox/flox ZfxWT/WT R26-CreER – mice 
generated by our BCC model crosses, yielding Ptch1flox/WT ZfxWT/Y hGFAP-Cre+ 
breeder males (Fig. 11A). These breeder males could then be crossed to other 
Ptch1flox/flox ZfxWT/WT R26-CreER – females, yielding both additional breeder males 
and also Ptch1flox/flox ZfxWT hGFAP-Cre+ (designated Ptch1 in Figures) males and 
females that would delete Ptch1 throughout their cerebella and develop MB (Fig. 
11B). Breeder males were also crossed with Ptch1flox/flox Zfxflox/flox R26-CreER – 
females, generating Ptch1flox/flox Zfxflox/Y hGFAP-Cre+ mice (designated Ptch1 Zfx) 
that co-delete Zfx along with Ptch1 (Fig. 11C). Ptch1 and Ptch1 Zfx mice, along 
with hGFAP-Cre – or Ptch1flox/WT littermate control animals (Ctrl), were monitored 
closely for disease progression and survival, and some mice were sacrificed at 
defined post-natal timepoints for analysis of their cerebella by histology (Fig. 12). 
  
Co-deletion of Zfx slows MB development and enhances survival after Ptch1 
deletion in vivo 
 To see whether Zfx co-deletion affected MB generation after Ptch1 
deletion in the cerebellum, we examined sagittal sections from cerebella of 
Ptch1, Ptch1 Zfx, and Ctrl mice at post-natal day 7 and 14 (P7 and P14)(Fig. 13). 
Unlike in the BCC model in the skin, co-deletion of Zfx did not prevent or 
drastically impair MB formation following Ptch1 deletion.  
  









Figure 13. Loss of Zfx delays Hh-induced MB development 
MB development was followed in mice with CNS-specific hGFAP-Cre and 
conditional alleles of Ptch1 alone (Ptch1) or of both Ptch1 and Zfx (Ptch1 Zfx), as 
well as in Cre- control mice (Ctrl). 
(A&B) H&E-stained sagittal sections of cerebella from P7 (A) and P14 (B) mice of 
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The massive expansion of the EGL and disruption of normal cerebellar foliation 
seen in P7 Ptch1 cerebella compared with P7 Ctrl cerebella was present also in 
P7 Ptch1 Zfx cerebella (Fig. 13A). Expansion of hyperproliferative EGL and 
disruption of normal cerebellar morphology was even more pronounced in both 
Ptch1 and Ptch1 Zfx cerebella at P14 (Fig. 13B). 
 While loss of Zfx did not appear, as with BCC, to stop MB formation in its 
tracks, visual inspection of sagittal sections from P7 and P14 Ptch1 Zfx cerebella 
suggested that loss of Zfx did result in reduced size of the MB-like expanded 
EGL and better preservation of cerebellar architecture (Fig. 13A&B). To confirm 
this observation, we quantified the size of MB tumor induced by Ptch1 deletion by 
measuring the cross-sectional area of the EGL (Fig. 14A) and non-EGL 
cerebellar tissue (Fig. 14B) in sagittal sections from Ptch1, Ptch1 Zfx, and Ctrl P7 
cerebella. Both Ptch1 and Ptch1 Zfx cerebella had significantly larger MB burden 
than Ctrl mice, as gauged by both cross-sectional area of the EGL (Fig. 14C) and 
by the percent of total cerebellar area occupied by EGL (Fig. 14D). However, 
Ptch1 Zfx P7 pups also had significantly smaller hyperproliferative EGL than 
pups that deleted only Ptch1, by EGL area (Fig. 14C) and percent cerebellar area 
(Fig. 14D). These data suggested that Zfx loss did not prevent but did slow the 
growth of MB after Ptch1 deletion. 
 Results from monitoring Ptch1 and Ptch1 Zfx MB mice for survival were 
concordant with the reduced MB tumor burden in Ptch1 Zfx mice observed by 
cross-section area measurements. All Ptch1 mice developed MB, with symptoms 
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Figure 14. Hh-dependent MB that co-delete Zfx have significantly smaller 
cross-sectional areas. 
To quantify the size of MB tumors generated in hGFAP-Cre+ Ptch1flox/flox ZfxWT 
(Ptch1), hGFAP-Cre+ Ptch1flox/flox Zfxflox/Y (Ptch1 Zfx), and Cre – or Cre+ Ptch1flox/+ 
(Ctrl) mice, we measured the cross-sectional area of hyperprolerative EGL in 
sagittal sections from P7 cerebella. 
(A) Representative micrographs showing measurement of cross-section area of 
external granular layer (EGL) or hyperproliferative EGL/MB tumor in sagittal 
cerebellar sections from P7 Ctrl, Ptch1, and Ptch1 Zfx pups. Sections are from 
same level (2nd out of 4 level sections through half cerebellum). 20x objective 
used, and area measurements made directly in Axionvision 4.8.2 software. 
 (B) Representative micrographs showing measurement of cross-section area of 
all cerebellar tissue excluding the EGL (non-EGL), in sagittal cerebellar sections 
from P7 Ctrl, Ptch1, and Ptch1 Zfx pups. Sections are from Level 2 out of 4 Level 
sections through half cerebellum. 20x objective used, and area measurements 
made directly in Axionvision 4.8.2 software. 
(C) Cross-section area of EGL in sagittal sections from P7 Ctrl, Ptch1, Ptch1 Zfx 
cerebella (n=7, 7, 6, respectively; mean + SD shown). Measurements made on 
sections from Level 2 of 4. ***, P<0.001. 
(D) Percent total cerebellar area comprised of EGL in sagittal sections from P7 
Ctrl, Ptch1, Ptch1 Zfx cerebella (n=7, 7, 6, respectively; mean + SD shown). 
Percent area computed as AreaEGL/(AreaEGL + AreanonEGL)*100. Measurements 
made only on sections from Level 2 of 4. **, P< 0.01; ***, P<0.001. 










Figure 15. Zfx co-deletion enhances survival in mice with MB induced by 
Ptch1 deletion 
Shown is a Kaplan-Meier survival plot for hGFAP-Cre+ Ptch1flox/flox ZfxWT (Ptch1) 
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including enlarged cranium, flattening of ears on the skull, and progressively 
worsening ataxia observable by eye by P14, and nearly all Ptch1 mice died or 
were sacrificed as moribund by 25 days of age (Fig. 15). This is an age 
consistent with the maximum survival age (~4 weeks) previously observed with 
this MB model 11, and one which corresponds to 4-6 days post-weaning, 
suggesting a possible failure to thrive independent of the dam. Meanwhile, all 
Ptch1 Zfx mice also developed MB, with the majority of Ptch1 Zfx mice (~70%) 
died around the same time (Fig. 15), likely also due to inability to survive the 
threshold effect of weaning. However, ~30% of Ptch1 Zfx mice survived past 
weaning and ~20% lived for >50 days, resulting in a significant improvement in 
survival (Fig. 15). Overall, these data suggest that the loss of Zfx slows MB tumor 
formation and prolongs survival in MB caused by Hh activation. 
 
Ptch1 Zfx mice develop Zfxnull MB after Ptch1 deletion in vivo 
 Previously we observed an outgrowth of Zfx non-deleter cells and failure 
to maintain Zfxnull cells in skin over the long-term following Tmx-induced co-
deletion of Zfx. Given that we observed Hh-dependent MB develop and ultimately 
cause the death of Ptch1 Zfx mice in vivo, we asked whether MB tumors in 
doubly-deleting Ptch1 Zfx mice would, as in the BCC model, be comprised of Zfx 
non-deleters. We stained sagittal sections from P7 cerebella of Ctrl, Ptch1, and 
Ptch1 Zfx mice with anti-Zfx antibody. While cells staining positive for nuclear Zfx 
were visible throughout normal EGL in Ctrl and MB-like EGL in Ptch1 cerebella, 
cells throughout the expanded EGL in Ptch1 Zfx cerebella stained negatively for 
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Zfx (Fig. 16A). Thus, in contrast with the results from our BCC model in the skin, 
Zfxnull MB do successfully develop following Ptch1 deletion in the cerebellum. 
 We also examined whether sections from Ptch1 and Ptch1 Zfx cerebella 
exhibited different levels of staining for proliferation markers. Towards this end, 
we stained sagittal sections from P7 cerebella of Ctrl, Ptch1, and Ptch1 Zfx mice 
with antibody against phosphohistone-3 (pH3), to mark cells in M-phase (Fig. 
16B). Counts of pH3+ cells in expanded EGL of Ptch1 and Ptch1 Zfx cerebellar 
showed no significant difference in frequency of proliferative cells between MB 
that did or did not co-delete Zfx (Fig. 16C). The above results from anti-pH3 
staining argued against any prolonged, global decrease in proliferative index as 
an explanation for the decrease in Zfxnull MB tumor size observed in doubly-
deleting Ptch1 Zfx cerebella (Fig. 14). 
 In the in vivo model of BCC initiated by Ptch1 deletion, Zfx co-deletion 
coincided with decreased expression of the signal transducer Smo and blunted 
overexpression of Hh targets Gli1 and Mycn. We asked whether the same 
changes in Smo and Gli1 expression occurred in our Hh-dependent MB model 
after Zfx co-deletion. Unlike the Tmx-inducible R26-CreER transgene used to 
induce BCC in the skin, hGFAP-Cre, the Cre line we employed to generate MB, 
does not allow for temporal control of its activity via Tmx administration and 
begins effecting Cre-mediated deletion in the mouse brain starting around E13.5 
127. As a result, instead of collecting tissue for gene expression analysis at a 
defined timepoint after induced deletion, as in the skin, we instead collected bulk 
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cerebella from a single, small cohort of Ctrl, Ptch1, and Ptch1 Zfx mice at P14, 
when the majority of cerebella of Ptch1 and Ptch1 Zfx mice are comprised of Hh-
dependent MB cells (Fig. 13B). Gene expression analysis on bulk P14 cerebella 
by qPCR showed decreased levels of Zfx mRNA in all hGFAP-Cre+ Zfxflox/Y mice, 
confirming successful Zfx ablation by hGFAP-Cre (and perdurance of Zfxnull cells 
in developing cerebella after Ptch1 deletion)(Fig. 17A). However, expression of 
the high-confidence Zfx target Dis3L was not substantially decreased in Ptch1 
Zfx P14 cerebella when compared with cerebella that delete Ptch1 alone (Fig. 
17B). Interestingly, Smo expression levels were higher in both Ptch1 and also in 
Ptch1 Zfx P14 cerebella (Fig. 17C). The Hh targets Gli1 and Mycn were also 
overexpressed comparably in both Ptch1 and Ptch1 Zfx P14 cerebella, compared 
with Ctrl mice (Fig. 17D&E).  
Collectively, these preliminary expression data suggest that, by P14 in the 
MB model system, Ptch1 Zfx cerebella exhibit neither the decreased Dis3L 
expression levels observed after Zfx loss in all tissues we’ve previously 
examined, nor reduced Smo levels or blunted activation of Gli1 and Mycn 
expression that we observed 3 days after Zfx co-deletion in the BCC model. To 
look at global changes in gene expression in P14 Ptch1 Zfx cerebella compared 
with Ptch1 and Ctrl (hGFAP-Cre-) cerebella, we performed a microarray analysis 
using RNA isolated from bulk cerebellar cells from P14 Ptch1 Zfx (n=2), Ptch1, 
and Ctrl cerebella (Fig. 18). Hierarchical clustering analysis of microarray data 
showed Ptch1 and Ptch1 Zfx P14 cerebella clustering closely together and 
   
72 
separately from Ctrl cerebella (Fig.18A). Only 10 genes were overexpressed > 2-
fold specifically in the Ptch1 Zfx cluster, compared to other nodes in the 
dendrogram (Fig. 18A). Direct comparison of expression data revealed that only 
64 genes were overexpressed and 29 genes underexpressed by more than 2-
fold in Ptch1 versus Ptch1 Zfx P14 cerebella (Fig. 18B). Additionally, principle 
component analysis of microarray data for a curated list of 9765 significant genes 
demonstrated that the first principle component, accounting for the great majority 
of the variation in the expression data (83%), corresponded to genes whose 
expression changes similarly in both Ptch1 and Ptch1 Zfx cerebella compared to 
Ctrl (Fig. 18C). Thus, microarray analysis from P14 cerebella suggests that the 
gene expression signature of Ptch1 and Ptch1 Zfx are very close to identical, and 
that doubly-deleting Ptch1 Zfx MB express very few genes differentially 
compared to Ptch1 MB by the time the affected mice reach post-natal day 14. 
 
Loss of Zfx alone does not impair normal cerebellar development in mouse 
 Data collected up to this point showed that Zfx co-deletion delayed (but did 
not stop) MB progression following Ptch1 deletion. One possible explanation for 
this phenotype, given the almost global range of deletion by hGFAP-Cre in the 
cerebellum, is that Zfx loss negatively affects normal cerebellar development and 
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Figure 16. Co-deletion of Zfx does not prevent MB development or alter 
proliferation profile after Ptch1 deletion in vivo 
(A) Zfx expression in cerebella after Ptch1 deletion, with or without Zfx co-
deletion. Shown are representative micrographs of anti-Zfx immunostainings of 
sagittal sections from P7 cerebella from Ptch1, Ptch1 Zfx, and hGFAP-Cre – or 
hGFAP-Cre+ Ptch1flox/WT (Ctrl) mice. Scale bars represent 100 µm. 
(B) Expression of the proliferation marker phosphohistone 3 (pH3) in P7 
cerebella after Ptch1 deletion and Zfx co-deletion. Shown are representative 
micrographs of anti-pH3 IHC stainings of sagittal sections from P7 cerebella from 
Ptch1, Ptch1 Zfx, and hGFAP-Cre – or hGFAP-Cre+ Ptch1flox/WT (Ctrl) mice. 
(C) Density of pH3+ proliferating cells in hyperproliferative EGL of P7 cerebella. 
Sagittal sections from corresponding level sections (2 of 4) from Ptch1 (n=7), 
Ptch1 Zfx (n=6), and Cre – (Ctrl) (n=3) P7 cerebella were stained with anti-pH3 
antibody, and cells in EGL with DAB-marked, pH3+ nuclei were counted. Density 
of pH3+ mitotic cells was computed by dividing the counts by cross-section EGL 
area (cf. Figure 14). Error bars represent SD. 
 
  




















































! Cre – Ptch1flox/WT ZfxWT/Y!
Cre – Ptch1flox/WT Zfxflox/Y!
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Figure 17. Zfx loss does not blunt increase in expression Smo and Hh 
target Gli1 in cerebella after Ptch1 deletion 
Expression levels of Zfx (A), the Zfx target Dis3L (B), Smo (C), and Hh pathway 
target genes Gli1 (D) and MycN (E) in RNA from bulk cerebellum isolated from 
P14 mice with the genotypes: Cre- Ptch1flox/WT ZfxWT/Y (n= 1), Cre- Ptch1flox/WT 
Zfxflox/Y (n=1), hGFAP-Cre+ Ptch1flox/WT Zfxflox/Y (n=1), hGFAP-Cre+ Ptch1flox/flox 
ZfxWT/Y (n=2), and hGFAP-Cre+ Ptch1flox/flox Zfxflox/Y (n=2). Shown are expression 
levels for individual mice, standardized for total RNA content using HPRT as a 
control gene and normalized to expression levels in Cre- Ptch1flox/+ ZfxWT/Y 
cerebellum, as determined by qPCR. Error bars represent SD of triplicate rxns. 
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Figure 18. Minimal changes in gene expression signature in P14 cerebella 
co-deleting Zfx compared to P14 cerebella that delete Ptch1 alone 
 
Gene expression analysis was performed using Affymetrix Mouse Gene ST1.0 
arrays on RNA purified from bulk cerebellar cells, isolated from postnatal day 14 
(P14) pups that delete Patched1 alone (Ptch1, n = 2), P14 pups that delete both 
Patched1 and Zfx (Ptch1 Zfx, n = 2), or control P14 pups that are hGFAP-Cre- 
(Ctrl, n = 2). The breeding scheme to generate these mice is explained in Figure 
11. Analysis of microarray data was performed using NIA Array. 
(A) Clustering analysis on gene expression array data from Ptch1, Ptch1 Zfx, and 
Ctrl P14 cerebella. Minimal fold change threshold was 2-fold. Numerical values at 
each node indicate the number of specific genes > 2-fold overexpressed in that 
nodal cluster compared to all samples outside that cluster. 
(B) Scatterplot depicting comparison of array data from Ptch1 (n = 2) and Ptch1 
Zfx (n = 2) P14 cerebella. Shown are genes significantly overexpressed (n = 64) 
or underexpressed (n=29) in Ptch1 cerebella compared to Ptch1 Zfx. Threshold 
fold-change in expression was set to 2-fold. 
(C) Principal component analysis of microarray data from P14 hGFAP-Cre 
cerebella. Shown are principal components from a 3-component analysis of the 
Ptch1, Ptch1 Zfx, and Ctrl microarray data. Percent contribution from each 
component is shown in the lefthand panels. Fold-change threshold was set at 2-
fold, and the NIA Array-curated list of 9765 significant genes were analyzed.  
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 with Hh or other pathways activated by Ptch1 deletion. To examine this 
possibility, we generated hGFAP-Cre+ Zfxflox/Y mice that delete Zfx alone, without 
any concomitant Ptch1 deletion or MB generation. These mice survived up until 
293 days of age (P293), and H&E staining of sagittal sections from P24 and 
P293 hGFAP-Cre+ Zfxflox/Y cerebella showed no gross abnormalities in cerebellar 
growth or foliation (Fig. 19). Immunohistochemical staining of P293 cerebellar 
sections for Zfx confirmed that hGFAP-Cre+ Zfxflox/Y cerebella were indeed 
comprised of Zfxnull cells (Fig. 19). Together, these results demonstrated deletion 
of Zfx alone throughout the cerebellum did not derail normal cerebellar 
development. 
 
Zfx is not required for tumor progression in a PTEN-dependent glioblastoma 
model in vivo 
 Another possibility, given the delaying effect on MB progression due to Zfx 
deletion, was that there existed a general requirement for Zfx across brain tumor 
types. To explore this possibility, we collaborated with researchers in the Canoll 
laboratory to generate a system to induce PTEN-dependent glioblastoma (GBM) 
in adult mice, with or without concomitant deletion of Zfx in the GBM tumor. Mice 
homozygous for a conditional Ptenflox allele (designated Pten mice) were bred to 
conditional Zfxflox/flox mice, yielding doubly-conditional Ptenflox/flox Zfxflox mice 
(designated Pten Zfx). Stereotactic injection of retrovirus delivering platelet-
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derived growth factor (PDGF) and Cre recombinase was performed into the 











Figure 19. Loss of Zfx does not affect normal cerebellar growth 
hGFAP-Cre+ Zfxflox/y mice with brain-specific Zfx deletion have normal lifespan 
and lack obvious pathology (not shown). hGFAP-Cre+ Zfxflox/y mice were 
sacrificed at post-natal days 24 (P24, n=2) and 293 (P293, n=2). Shown are 
representative cerebellar sections stained with H&E or immunostained with anti-
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aggressive Pten-deficient GBM of the proneural subtype 128. After viral delivery 
and GBM initiation, Pten Zfx mice did not exhibit enhanced survival compared to 
the Zfx-retaining Pten mice (Fig. 20A), displaying instead a tendency towards 
slightly worsened survival. IHC staining with anti-Zfx antibody confirmed that 
GBM that developed in Pten Zfx mice were indeed comprised of Zfxnull cells, not 
Zfx non-deleters (Fig. 20B). These results suggested that Zfx is not required in 
Pten-dependent GBM in vivo and argue against a generalizable requirement for 
Zfx across all different brain tumor types.  
 
ZFX knockdown impairs cell proliferation in a human MB cell line in vitro 
 Finally, given the delay in MB progression after Zfx deletion in mouse 
cerebella in vivo, we asked whether loss of ZFX would impair growth of human 
medulloblastoma in vitro. We used the commercially available human MB cell-
line DAOY 129, which has the advantage of having lost the Y chromosome, 
thereby removing possible confounding effects from the ZFX homolog, ZFY. To 
determine whether loss of ZFX effects human MB cells in vitro, we knocked down 
ZFX in DAOY cells using lentivirally-delivered short hairpin RNAs (shRNA), a 
recently validated system used to knock down ZFX in human embryonic stem 
cells (ESC) 75. 
 DAOY human MB cells were transduced with lentiviral vectors encoding 
one of three ZFX-specific shRNAs (H2, H3, H4), or a control “scrambled” (SCR) 
shRNA. Two ZFX-specific shRNAs (H2, H3) strongly reduced Zfx protein (Fig. 
21A) and transcript (Fig. 21B) levels in transduced DAOY cells, whereas the third 
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(H4) caused a more moderate reduction (Fig. 21B). Additionally, these ZFX-
targeting shRNAs impaired the growth of DAOY cells, compared to cells 
transduced with SCR control shRNA (Fig. 21C). The degree of growth 
impairment scaled roughly proportionately to the degree of ZFX knockdown 
observed by qPCR (Fig. 21B,C). Taken together, results from lentiviral 
knockdown in DAOY cells suggest that ZFX is required for optimal growth of a 
human MB cell line in vitro. 
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Figure 20. Loss of Zfx does not impair Pten-dependent glioblastoma 
development 
(A) Kaplan-Meier survival curve for retrovirus-injected Pten and Pten Zfx mice. 
Glioblastoma was induced via stereotactic injection of retrovirus encoding PDGF 
and Cre recombinase into brains of young adult mice with conditional null alleles 
of Pten only (Pten) or of both Pten and Zfx (Pten Zfx). 
(B) Immunohistochemical staining for Zfx in sections of glioblastomas from 
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Figure 21. Zfx knockdown impairs cell proliferation in a human MB cell line 
in vitro 
The human MB cell line DAOY was transduced in vitro with lentiviruses encoding 
short hairpin RNAs (shRNAs) targeting ZFX transcript (H2, H3, H4) or a 
scrambled control shRNA (SCR). Transduced cells were selected for by growth 
in puromycin-containing medium. 
(A) Western Blot for ZFX (green) and tubulin control (Tub, red) in DAOY cells 
transduced with control (SCR) or ZFX-targeting (H2, H3) lentivirus. 
(B) Expression of ZFX in DAOY cells after shRNA knockdown. Shown are ZFX 
expression levels 4 days after transduction, as determined by qPCR (mean ± SD 
of triplicate parallel cultures; representative of three independent experiments). 
(C) Growth curves for DAOY cells transduced with lentivirus expressing control 
(SCR) or ZFX-targeting (H2, H3, H4) shRNA (mean ± SD of triplicate parallel 
cultures, representative of three independent experiments). 
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Discussion 
 In this Chapter, we investigated whether the transcription factor Zfx was 
required for the development of a second type of Hh pathway-driven cancer, 
using mouse models of MB. MB were generated using nearly CNS-wide ablation 
of Hh inhibitory receptor Ptch1 by hGFAP-Cre, and co-deletion of Zfx in cerebella 
of Ptch1 Zfx mice delayed but did not stop MB progression (Fig. 13). Mice co-
deleting Zfx along with Ptch1 had smaller MB tumors, or hyperproliferative EGL 
(Fig. 14), which correlated with a significant enhancement in survival times (Fig. 
15). In contrast, Zfx co-deletion conferred no survival enhancement in a PTEN-
dependent model of glioblastoma (Fig. 20). These results argue in favor of a 
requirement for Zfx for the optimal growth of Hh-driven MB in vivo, but against a 
generalized requirement for Zfx across all brain tumor types. 
 In Chapter I, we reported a requirement for Zfx for Hh-driven BCC 
development in the skin. Combined with our results from the Ptch1-dependent 
MB model summarized above, we have evidence for a common requirement for 
Zfx across two very different Hh pathway-driven cancers. Other genes outside of 
Hh pathway components have been shown to affect both MB and BCC, such as 
the tumor suppressor p53, whose loss in p53 -/- Ptch1+/- mice has been shown to 
promote Hh-driven MB 130 and BCC formation 8. Zfx is an interesting case, 
however, as it is neither an oncogene nor a tumor suppressor gene in this 
context, but merely an unmutated “normal cellular function” gene which is 
required in both MB and BCC. This dual requirement across MB and BCC 
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highlights Zfx and its downstream transcriptional targets as a novel cell-intrinsic 
machinery linking Hh-dependent cancers. 
 Although Zfx is required for optimal growth of both BCC and MB, there are 
clear qualitative differences between the effects of Zfx loss on Hh-driven BCC 
and those on Hh-driven MB. In BCC models, co-deletion of Zfx was incompatible 
with BCC development. In the case of MB, Zfxnull MB clearly develop and grow 
out (Fig. 16A). Expanded EGL in Ptch1 Zfx mice are significantly smaller than in 
the Ptch1 only mice at P7, but they are still clearly expanded, full of 
hyperproliferative GNP, and significantly larger than wild-type EGL (Fig. 14). A 
fraction of Ptch1 Zfx mice survive far longer with their Hh-driven MB than do mice 
which only delete Ptch1, but they all still succumb to MB (Fig.15). Loss of Zfx 
more weakly impairs Hh-driven MB than it does BCC. 
 In searching for an explanation for the effects of Zfx loss on Hh-driven MB 
models in vivo, one possibility is that phenotypes we observe in Ptch1 Zfx 
cerebella are the result of continual effects from Zfx loss spanning the entire 
embryonic and post-natal development of the cerebellum. If this were to be the 
case, we could draw some conclusions from analyses of P7 and P14 cerebella. 
Ptch1 Zfx P14 cerebella exhibit the same heightened expression of Smo and Hh 
targets Gli1 and Mycn as Ptch1 singly-deleting cerebella (Fig. 17C-E), arguing 
against transcriptional regulation of Smo by Zfx in this MB model. Lack of major 
disruption in cerebellar development in P21 and P293 hGFAP-Cre+ Zfxflox/Y mice 
(which delete Zfx alone)(Fig. 19) supports the conclusion that Zfx does not 
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regulate Smo expression throughout cerebellar development, since even graded 
disruption of the Hh pathway will generate observable defects in cerebellar 
foliation patterns 23.  
Additionally, decreased GNP proliferation does not appear to account for 
the delayed growth of MB in Ptch1 Zfx doubly-deleting mice, since counts of 
mitotic pH3+ GNP from expanded EGL are not significantly different between P7 
cerebella in Ptch1 and Ptch1 Zfx mice (Fig. 16B,C). In place of a difference in 
proliferation profile, the delayed MB growth following Zfx loss could also be 
accounted for by increased cell-death, or by introduction of a bias in transformed 
Ptch1CKO GNP away from self-renewal and towards differentiation in mature 
neurons. The expanded EGL in Ptch1-dependent MB mice is not a monoculture 
of hyperproliferative GNP but also included regions of differentiated neurons, 
which can be distinguished by staining for markers like NeuN or synaptophysin 
11. Staining sections from Ptch1 Zfx cerebella for markers of mature neurons 
could determine whether Zfx co-deletion slows Hh-driven MB via biasing 
transformed GNP towards differentiation. A similar bias towards differentiation 
after Zfx deletion has already been observed in unpublished work from our 
laboratory in a different cancer model, where leukemic blasts from MLL-AF9-
driven acute myeloid leukemia (AML) adopt a more differentiated myeloid 
phenotype following Zfx deletion (S. Weisberg, unpublished data). 
 Alternatively, Zfx loss could have its effects on Hh-driven MB development 
over a restricted time-period, perhaps very early after targeted co-deletion of 
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Ptch1 and Zfx. At P14, there is no difference in Smo expression between Ptch1 
and Ptch1 Zfx cerebella, and they have the same density of mitotic pH3+ GNP at 
P7. However, while placed near the peak and near the eventual fall-off in post-
natal GNP proliferation for wild-type cerebella, these time-points are actually 
capturing relatively late events in the hGFAP-Cre Ptch1flox mouse model. The 
hGFAP-Cre transgene begins deleting in the brain as early as E13.5 127, and 
hyperproliferation of GNP and expansion of the EGL is already readily 
observable in E16.5 cerebella 11.  The requirement for Zfx in Hh-driven MB - - 
whether through regulation of Smo, proliferation-related genes, or other 
downstream targets altogether - - could be temporally restricted to some portion 
of embryogenesis after E13.5, or to earliest post-natal days. Subsequently, the 
Hh-driven MB in Ptch1 Zfx mice could escape a requirement for Zfx, looking like 
MB in Ptch1 only mice by P7 and P14. Additional transcription factors could also 
compensate for Zfx loss, supplementing expression of Zfx targets in its absence. 
Expression analyses of P14 cerebella by both qPCR and microarray argue 
support the hypothesis that Zfx loss has temporally-restricted effects that are lost 
or compensated for by other transcription factors by P14. For example, there is 
only a minimal decrease in the expression of the Zfx target gene Dis3L in Ptch1 
Zfx P14 cerebella (Fig. 17B). Furthermore, microarray analysis comparing gene 
expression in P14 cerebella showed Ptch1 and Ptch1 Zfx samples clustering 
together and separately from Ctrl samples (Fig. 18A). Microarray data also 
revealed very few gene expression differences by P14 between singly- and 
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doubly-deleting cerebella (Fig. 18B, C). These results argue in favor of a 
temporally-restricted role for Zfx in this Hh-driven MB model (one which is lost by 
P14), and they suggest that further investigation is warranted into transcription 
factors that could bind to GGCCT-rich Zfx binding sites and compensate for Zfx. 
Math1-CreER Ptch1flox mice, a previously validated model for generating 
Hh-driven MB 11, offer many attractions as a system for validating this putative 
temporally-restricted role for Zfx in MB. Math1-CreER is expressed specifically in 
GNP, the MB cells-of-origin, and its Cre recombinase activity is Tmx-inducible, 
allowing for controlled MB induction at defined post-natal time-points and 
exploration of early events following Ptch1 ablation and Zfx co-deletion. 
Additionally, the kinetics of MB disease generated by Math1-CreER are much 
slower, with pups induced with Tmx at P4 having 12 weeks median survival, 
compared to 3-4 weeks maximum in hGFAP-Cre Ptch1flox mice 11. Thus, 
generation of Zfx-deficient MB using Math1-CreER is an attractive possibility also 
for its ability to bypass threshold effects of weaning on survival curves, as well as 
for its potential to verify that the biphasic survival curve in Ptch1 Zfx mice (Fig. 
15) is indeed an artifact due to weaning age and not attributable to issues with 
the mixed mouse background. 
 In Chapter I, we showed a requirement for Zfx in Hh-dependent BCC. In 
this Chapter, we demonstrated that Zfx loss delays Hh-driven MB development in 
vivo. In Chapter III, we will explore further the downstream direct targets of Zfx 
and their functional relevance in these two Hh-dependent cancers. Evidence for 
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the transcriptional regulation of Smo by Zfx will be examined and evaluated as an 
explanation of the phenotypes from Zfx loss in BCC and MB. Additionally, the 
sensitivity of DAOY human MB cells to ZFX loss (Fig. 21) will be utilized, in 
concert with ChIP-seq and gene expression microarray assays, to identify 
conserved direct transcriptional targets of ZFX that are candidate members of a 
novel cell-intrinsic machinery shared by MB and BCC. 
 
 
Materials & Methods 
 
Animals 
Mice with a conditional allele of Ptch1 (Ptch1flox)105 were bred with 
conditional Zfxflox mice74 to generate singly- and doubly-conditional Ptch1flox/flox 
and Ptch1flox/flox Zfxflox/y mice. Ptenflox mice131 were similarly crossed to Zfxflox 
mice to generate Ptenflox/flox and Ptenflox/flox Zfxflox/y mice. To generate Hh-
dependent medulloblastoma (MB) in vivo, hGFAP-Cre mice127 were obtained 
from the Jackson Laboratory and crossed with Ptch1flox and Ptch1flox Zfxflox mice 
to generate hGFAP-Cre+ Ptch1flox/flox (hGFAP-Ptch1) and hGFAP-Cre+ 
Ptch1flox/flox Zfxflox/y (hGFAP-Ptch1-Zfx) experimental animals, along with hGFAP-
Cre- littermate controls (Ctrl). All animal studies were performed according to the 
investigator’s protocol approved by the Institutional Animal Care and Use 
Committee of Columbia University. 
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Cell Culture 
DAOY cells were obtained from the ATCC and propagated in complete 
DMEM medium with 10% FBS, and replated by trypsinization. 
 
RNA Isolation and qPCR 
Total cellular RNA was isolated from samples in 0.5-1 mL TriZol LS 
reagent (Invitrogen).  cDNA was synthesized from 1-2 µg RNA per sample using 
SuperScript III reverse transcriptase (invitrogen). Quantitative real-time PCR 
(qPCR) assaying for SYBR Green incorporation were run on an Mx3000P 
instrument (Stratagene) using FastStart Universal SYBR Green Master mix 
containing Rox (Roche). Triplicate reactions were run for each sample, and all 
qPCR results were analyzed using the ΔΔCt method. The expression values for 
all genes were scaled to total RNA content using Ct for the housekeeping genes 
β-Actin (Actb), β2-microglobulin (B2m), hypoxanthine guanine phosphoribosyl 
transferase (HPRT), or GAPDH, and then normalized to the indicated control 
samples. The qPCR primers are listed below. 
Species Gene Forward Reverse 
Mouse Actb ATCCTGACCCTGAAGTACC TACGACCAGAGGCATACAG 
 B2m ACCCTGGTCTTTCTGGTGCTTG TATGTTCGGCTTCCCATTCTCC 
 HPRT GCCCCAAAATGGTTAAGGTTGC TCAAGGGCATATCCAACAACAAAC 
 GAPDH AAGGTCGGTGTGAACGGATTTG CTCGCTCCTGGAAGATGGTGAT 
 Zfx GCAGTGCATGAACAGCAAGT GCAAGGTGTTCAGGATGGTT 
 Dis3L AGGGGGAAGCCATGGAGAAG GATTTGATGCCCGCTTCCAG 
 Ube2j1 GACGCATAGTACTGCCACCA ATGGCCCCCTCTCCTTTAGT 
 Smo CTCGGACTCGCAGGAGGAAG TCAGGGAAGTGGTCCGGTGT 
 Gli1 CATTGGGGAGGTTGCTCCAG CCGAAGGTGCGTCTTGAGGT 
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 Mycn GGAGAGGATACCTTGAGCGACTC CGCCTTGTTGTTAGAGGAGGAAC 
 Mnx1 AGGCGCAGTCGAACCTCTTG TCCATTTCATTCGGCGGTTC 
 Isl1 CAAGCGGTGCAAGGACAAGA CAGGGCGGCTGGTAACTTTG 
 Olig2 CACCTCCTCGTCCACGTCCT GGCGATCTTGGAGAGCTTGC 
 Tubb3 GGCCATTCTGGTGGACTTGG GCCCTGCAGGCAGTCACAAT 
Human GAPDH AAGGTGAAGGTCGGAGTCAACG CCCACTTGATTTTGGAGGGATC 
 Zfx GCAGGATGATGACAAAGGCAAC CAAGGATCAATTTCCGACTCTGTG 
 Dis3L CCAGGACAGGATGCCAATTGTT CGTGGGCAGCTTTTAAATCAGG 
 Ube2j1 GAAACTTGGCAGCCTTCGTG ATGGCAGAGCCACATCCTTC 
 Smo GCTCATCGTGGGAGGCTACTTC AGCATGGTCTCGTTGATCTTGC 




RNA for microarray analysis of cerebella and MB after Zfx loss was 
obtained from bulk cerebellar cell suspensions from P14 cerebella of hGFAP-
Cre+ Ptch1flox/flox Zfxflox/Y (Ptch1 Zfx), hGFAP-Cre+ Ptch1flox/flox ZfxWT (Ptch1), and 
hGFAP-Cre – (Ctrl) mice . Labeled cDNA was analyzed on Affymetrix Mouse 
Gene 1.0 ST arrays. Analysis of microarray data was performed using NIA Array 
Analysis web tools 132. 
 
Glioblastoma Model 
Glioblastoma was induced by stereotactic injection into brain of young 
adult Ptenflox/flox and Ptenflox/flox Zfxflox/y mice of retrovirus coding for PDGF-IRES-
Cre as described.128 Treated animals were followed for survival, and brains from 
sacrificed animals were fixed and processed for histology and 
immunohistochemistry. 
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shRNA Constructs and Lentiviral infection of DAOY human MB cells 
Lentiviral constructs containing Zfx-targeting (H2, H3, H4) and non-
specific (SCR) short hairpin RNAs (shRNAs) in the pLKO.1 backbone were 
purchased from Open Biosystems. To generate high-titer lentivirus, HEK293T 
cells were co-transfected with three plasmids encoding viral packaging proteins 
(pCMV∆8.9), envelope proteins (pVSVg) and the pLKO.1 shRNA sequences 
using the lipid-based transfection reagent Transit-293 (Mirus, LLC). After 48 
hours incubation at 37°C, transfected cells were shifted to 32°C for 24 hours. 
Then viral supernatant was cleared using 0.45 micron filters and ultracentrifuged 
(50,000 x g, 2 hrs) to concentrate viral particles. 
 Triplicate cultures of 4x105 DAOY cells were plated out overnight and then 
incubated with concentrated lentiviral supernatant and 7 µg/mL polybrene for 16-
24 hrs, for a Mock, virus-less condition and for each lentiviral construct.  Cells 
were allowed to rest for 2 days and then replated and grown henceforth in 
selective media containing 2 µg/mL puromycin (invitrogen).  At 4 or 6 days post-
infection (d.p.i.), plates were washed with 1x DPBS, and cells were collected in 
TriZol LS reagent for gene expression analysis or scraped, collected by 
centrifugation, and lysed in RIPA buffer for Western Blot. 
 
Immunohistochemistry 
Brains isolated from P7 and P14 pups were fixed whole in zinc formalin for 
24-48 hrs, then cut in half sagittally and fixed for an additional 24-96 hrs before 
embedding each half separately in paraffin. Mice sacrificed after P19 were 
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cardiac perfused with zinc formalin prior to brain extraction. Sagittal paraffin 
sections (5 µm) were cut at 4 levels equally spaced across the cerebellum, with 
one slide stained with H&E at each level and with several blank slides cut and 
saved. For IHC, paraffin blanks were dewaxed and rehydrated, and antigens 
were unmasked by boiling for 15-20 minutes in 0.01 M sodium citrate buffer. 
Slides immunostained with rabbit polyclonal anti-Zfx antibody (1:500) or with anti-
phosphohistone 3 (pH3) antibody (Cell Signaling #9701, 1:200) were incubated 
overnight at 4 C in primary antibody, incubated with biotinylated anti-rabbit 
secondary antibody (Vector Labs) for one hour, visualized using ABC and DAB 
Peroxidase Substrate Kits (Vector Labs), and finally counterstained with 
hematoxylin. 
 Micrographs of histological sections were recorded using an 
AxioImager.M2 microscope with attached AxioCam MRc camera (Zeiss). 
Measurements of cross-section area in cerebellar paraffin sections were made 
using Axiovision 4.8.2. Scales bars were added in directly with the Axiovision 
4.8.2 software package. 
 
Statistics 
Cross-section cerebella area and percent area data and phosphohistone 3 
staining density data were analyzed by unpaired, two-tailed Student’s t-tests. 
Kaplan-Meier survival curves were analyzed with the LogRank test. 
 
 
















Zfx regulation of Hedgehog (Hh) signal transducer 
Smoothened (Smo) and novel downstream targets 
in the context of Hh­dependent cancers 
 
  




Molecular targeting of Hh-dependent BCC and MB 
 As discussed previously in Chapters I and II, basal cell carcinoma (BCC) 
and the Hh-dependent subtype of medulloblastoma (MB) represent a case of two 
very different cancers, highly divergent in cell-of-origin, age of onset, and clinical 
prognosis. BCC are slow-growing, rarely metastatic skin tumors that form mostly 
in adults and are rarely life-threatening 21. MB primarily develop in the cerebella 
of infants and children, and, while combination of chemotherapy and radiation 
therapies bring overall survival rates for Hh-driven MB to 60-80%, it is at the cost 
of often severe cognitive side effects in the treated children 67. Nevertheless, it 
has been shown that both BCC and a subset of MB are marked by a single root 
molecular alteration, the activation of the Hh signaling pathway 21, 67, with 
generation of BCC and MB by targeted activation of the Hh pathway confirmed in 
multiple mouse models 8, 10, 20, 133. 
 Molecular therapies targeting the Hh pathway thus offer the promise of an 
alternative avenue of attack against BCC and MB. Phase I clinical trials for 
vismodegib (GDC-0449), an orally-delivered small molecule inhibitor targeting the 
Hh signal transducer Smo, showed encouragingly positive outcomes, especially 
in the case of BCC 134. The majority of patients with local or metastatic BCC who 
were treated (18 out of 33, >50%) had either a partial or complete response to 
the vismodegib therapy 110. Trials in an adult patient with metastatic MB also 
provoked regression of the tumor following vismodegib treatment, although the 
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effect was temporary 135. Subsequently, efficacy and safety for vismodegib was 
confirmed in phase II trials 136, and vismodegib has since been approved by the 
Food and Drug Administration for treatment of patients with metastatic or locally 
advanced basal cell carcinoma 137. 
 Caveats and side-effects pertaining to the use of Hh pathway small 
molecule inhibitors in treating BCC and MB do exist, however, and must be 
considered. One problem is outgrowth of tumor cells that have acquired 
additional mutations (often in the targeted gene) that confer resistance to the 
small molecule therapy. This effect was already observed in small molecule 
targeting of Hh-dependent cancers, in the case of adult MB that transiently 
responded to Smo inhibitor vismodegib, where acquired resistance in the MB 
was linked to mutation of Smo 138. 
 Small molecule targeting of Smo and the Hh pathway is also problematic 
given its potentially adverse side effects, both during development in young 
patients and in adult patients. As was discussed in Chapter II, Hh signaling is 
essential for post-natal patterning of the developing cerebellum 117. MB is 
primarily a pediatric malignancy, potentially coinciding temporally with normal 
developmental stages in the post-natal cerebellum. Small molecule targeting of 
Hh pathway in pediatric MB could therefore risk negative side effects on patients’ 
cerebellar development 117, along with other developmental processes such bone 
growth, where defects have been detected after inhibition of the Hh pathway in 
young mice 139.  
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Furthermore, phase II trials with the Smo-targeting vismodegib in adult 
BCC patients showed that all treated adults exhibited at least one adverse side 
effect event 136. While the majority (57%) of treated patients exhibited only the 
milder Grade 1 or Grade 2 adverse events 136, these side effects included muscle 
spasms, alopecia, and dysgeusia, all conditions that are unpleasant to endure for 
the patient and that can prompt discontinuation of drug treatment. 
 
Targeting non-oncogene addiction for cancer therapy  
 An alternative to targeting molecular therapies against the oncogenes or 
tumor suppressors mutated in and driving different cancers is to instead identify 
and then target non-mutated housekeeping genes that are often dispensable in 
most normal cells but that become preferentially or essentially required in tumor 
cells. This phenomenon where certain genes involved in normal cellular 
processes become absolutely required in the context of proliferating cancer cells, 
without being mutated as either a tumor suppressor gene or oncogene, has been 
referred to as non-oncogene addiction 140. Cell-intrinsic non-oncogene addiction 
often centers on genes pertaining to stresses occurring in tumor cells, such as 
metabolic stress, DNA damage/repair, proteotoxic stress, or oxidative stress 140. 
Examples of targeting cell-intrinsic non-oncogene addiction in these stress 
scenarios include inhibiting proteasome function with bortezomib to increase 
proteotoxic stress and kill multiple myeloma 141, or inhibiting an enzyme like 
PARP1, important in DNA single strand break repair, to exacerbate DNA damage 
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stress in cancer cells that have mutated BRCA2  and are already deficient in 
DNA repair by homologus recombination 142, 143. Identification of similar cases of 
non-oncogene addiction spanning BCC and MB could provide alternative 
avenues for delivery of targeted therapies against the two different Hh-dependent 
tumors, beyond small molecule inhibitors that hit Smo directly and through it Hh 
pathway activity. 
 
 Conserved direct targets of Zfx and their functional relevance in MB & BCC 
 In results from Chapters I and II, we showed a partial or complete 
requirement for the transcription factor Zfx in the development of MB and BCC 
after Hh pathway activation in mouse brain and skin. Here, we propose Zfx as a 
candidate for an example of non-oncogene addiction common across the two 
disparate Hh-dependent cancers. In this Chapter, we sought to identify direct 
downstream transcriptional targets of Zfx which had functional relevance in BCC 
and MB models and could explain the requirement for Zfx in Hh-dependent 
cancers. Using massively parallel sequencing of genomic DNA captured by anti-
ZFX chromatin immunoprecipitation (ChIP-seq) from human DAOY MB cells, we 
found 3000+ conserved direct binding targets of ZFX that were shared in ChIP-
seq from mouse ESC 70. Among the direct ZFX targets, we identified the Hh 
pathway signal transducer, SMO, whose altered expression after Zfx deletion in 
BCC in vivo and in MB in vitro suggested that Zfx regulation of Smo could explain 
in part the observed requirement for Zfx in BCC and MB. Additionally, we 
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identified a shortlist of 30 target genes which are bound in Zfx ChIP-seq from 
both mouse and human and which are also downregulated after ZFX knockdown 
in human MB cells in vitro. Knockdown of two target genes from this list, DIS3L 
and UBE2J1, impaired growth of human MB in vitro. Preliminarily, our results 
pointed towards the shortlisted downstream targets of ZFX, such as DIS3L and 




Finding direct ZFX targets with ChIP-Seq in DAOY human MB cells 
 In the preceding chapters, data was presented showing a requirement for 
the transcription factor Zfx in mouse models of Hh-dependent BCC and MB in 
vivo, as well as in the human MB cell-line DAOY in vitro. In order to understand 
why the loss of Zfx has these effects, we proposed to identify downstream direct 
transcriptional targets of Zfx, some subset of which are presumably relevant in 
causing the observed phenotypes in BCC and MB models in vivo and in vitro. As 
a first step, we set out to identify genomic direct binding targets of ZFX protein 
using chromatin immunoprecipitation assays followed by massively parallel DNA 
sequencing of the chromatin-bound genomic DNA fragments (ChIP-seq). 
 We performed ChIP-seq on anti-ZFX ChIP samples from nuclear lysate of 
DAOY human MB cells, using nuclear lysate that wasn’t subjected to ChIP as a 
control (Input). Analysis of resulting ChIP-seq data using MACS peak-picking 
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software144 yielded over 14,400 sequence-read enrichment peaks in anti-ZFX 
ChIP-seq compared with Input control. We began basic characterization and 
analysis of this dataset, in an effort to whittle a bewilderingly long list of binding 
peaks down to more tractable shortlists of potentially relevant ZFX targets. 
 First, we looked at the proximity of ZFX ChIP-seq enrichment peaks to 
adjacent genes. When we grouped ZFX binding peaks into 200 bp-wide “bins” 
ranging in either direction away from the transcriptional start site (TSS) of the 
nearest gene, we found that the majority of ZFX binding peaks identified by ChIP-
seq in DAOY were located very close to TSS of the nearest adjacent gene (Fig. 
22A), with the majority residing within 500 bp of TSS. Additionally, we applied the 
ChIPseeqer FIRE analysis module to our ZFX ChIP-seq dataset to identify short 
oligonucleotide binding motifs over- or underrepresented in the ZFX binding 
peaks. Encouragingly, the two highest-scoring motifs picked as overrepresented 
in our ZFX enrichment peaks from ChIP-seq included AGGCC (Fig. 22B, 23), the 
reverse complement of the GGCCT consensus sequence previously identified as 
the motif recognized by Zfx 70,71, 72.  
 We next asked how our list of ZFX binding targets identified in a human 
MB cell-line compared against other lists of ZFX binding targets generated by 
ChIP-seq in different biological contexts. Specifically, we compared our ZFX 
ChIP-seq target genes from DAOY cells with Zfx direct targets identified by 
another laboratory from ChIP-seq in murine embryonic stem cells (ESC) 70. Given 
that the great majority of ZFX binding peaks occurred very close to TSS of the 
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nearest gene (Fig. 22A), we focused our comparison only on ChIP-seq peaks 
within 1 kb of TSS. We found that there was a high degree of overlap between 
the two lists of Zfx ChIP-seq binding peaks, with 62% of Zfx targets in mESC 
(3038) also bound in DAOY cells (Fig. 22C). Together, this overlap ChIP-Seq 
gene-list comprised a pool of Zfx direct binding targets conserved across 
species.  














Figure 22. Direct binding targets of ZFX from ChIP-Seq in human MB and 
murine ESC 
(A) Distribution of ZFX binding peak distances from gene transcription start sites 
(TSS) from anti-ZFX ChIP-seq in DAOY human MB cells. Shown are 
percentages of total ZFX binding peaks at binned 200 bp distances from TSS. 
(B) Motifs overrepresented in ZFX binding enrichment peaks from ChIP-seq in 
human DAOY cells, identified by unbiased analysis with ChIPseeqerFIRE 
module.145 
(C) Comparison of non-redundant ZFX binding enrichment peaks >1 kb from 
TSS in ChIP-seq from DAOY human MB and from murine ESC.70 
 
  

































































Figure 23. de novo motif analysis of ZFX ChIP-seq in DAOY human MB  
ZFX binding peaks identified using MACS (1.4.0) from ChIP-seq in human DAOY 
medulloblastoma cells were analysed for unbiased/de novo discovery of binding 
motifs using the ChIPseeqerFIRE module of ChIPseeqer (2.0).145 Shown are the 
summarized results displaying optimized motifs picked by ChIPseeqerFIRE for 
underrepresentation (uppermost two entries) or overrepresentation (lower five 
entries) in the ZFX binding peaks sequence from ChIP-seq in DAOY cells. 
Highlighted motifs (red) had the highest z-score of motifs overrepresented in ZFX 
ChIP-Seq peaks, and they contain sequence complementary to the GGCCT 
previously identified as the Zfx binding motif 70, 71, 72. 
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Zfx facilitates the expression of the Hh signal transducer Smo 
 We refocused our search for downstream targets of ZFX with potential 
explanatory power onto these 3038 conserved Zfx binding targets. Given 
observed effects of Zfx loss in Hh-dependent MB and BCC cancer models in 
vivo, we first scanned the common ChIP-seq gene-list for core components of 
the Hh signaling pathway. A core pathway component found in the overlap list 
was Smo, a promising candidate given that it encodes the non-redundant signal 
transducer of the Hh signaling pathway. There were Zfx binding enrichment 
peaks near the TSS of Smo in ChIP-seq data from both mESC (Fig. 24A) and 
DAOY human MB (Fig. 24B), confirming Smo as a Zfx-bound gene in both 
mouse and human cells in vitro.  
We then asked whether we could find evidence for changes in the 
expression levels of Smo and Hh pathway components following Zfx loss, 
particularly in the context of BCC or MB models in vivo and in vitro. Looking 
again at the human MB cell-line DAOY, decreased ZFX expression after lentiviral 
shRNA knockdown (KD) of ZFX correlated with reduced SMO expression (Fig. 
24C). We also saw additional evidence for transcriptional regulation of Smo by 
Zfx earlier in Chapter I. When we examined gene expression by qPCR in bulk 
epidermis and hair follicles from Ptch1 and Ptch1 Zfx mice 3 days after Tmx 
application to induce Hh-dependent BCC, co-deletion of Zfx in Ptch1 Zfx skin 
decreased Smo expression levels and prevented the induction of Hh pathway 
targets Gli1 and MycN (Fig. 25). These data point towards a requirement for Zfx 
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for optimal Smo expression, in both DAOY MB cells in vitro and also in the 
context of a model of Hh-dependent BCC in mouse skin. 
Given the correlation of Zfx loss with decreased Smo expression observed 
across cell-types and species, we next investigated whether Zfx was generally 
required for Hh signaling during normal development. Previous work from our 
laboratory suggested that Zfx is dispensable for Hh signaling during normal 
embryonic development 74. Pups deleting Zfx throughout the embryo-proper die 
perinatally 74, but they exhibit none of the major skeletal or nervous system 
defects associated with the complete blockade of the Hh pathway that would 
results from loss of Smo expression 26. To confirm that Zfx is dispensable for Hh 
signaling during normal development, we tested whether ZfxCKO embryos had 
defects in the specification of floor plate and of motor neuron pools in the 
developing ventral spinal cord, a process known to depend on active Hh 
signaling 55, 116. Shh-/- or Smo-/- embryos that lack active Hh signaling fail to 
develop floor plate and have smaller and highly disorganized motor neuron pools 
in their ventral spinal cord 55, 116. We examined ZfxCKO embryos at E13.5/E14.5 to 
determine whether they establish floor plate and motor neuron pools in their 
developing spinal cord (Fig. 26). Embryos that conditionally deleted Zfx stained 
positively for floor plate in their developing spinal cord comparably to Sox2-Cre- 
littermate control embryos (Fig. 26A), as confirmed by immunostaining for the 
established floor plate marker FOXA2/HNF-3β 146, 147. Furthermore, 
immunostainings for the motor neuron marker HB9/Mnx1 reveal that ZfxCKO 
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embryos also successfully form motor neuron pools that are grossly comparable 
to Ctrl embryos (Fig. 26B).  
While Zfx loss may not impair Hh signaling during normal embryonic 
development, Zfx-dependent regulation of Smo expression could still play a role 
in the context of biological systems where the Hh pathway is overactivated. 
Heterozygous Smo+/- embryos are wild-type in appearance and display none of 
the defects associated with Smo-/- full knockouts 44, 116, suggesting that 
decreases in Smo levels on the order of 2-fold may not significantly impair Hh-
dependent developmental processes. However, modest decreases in Smo 
expression levels due to Zfx loss could impact systems with hyperactivated Hh 
signaling from superabundance of Hh ligand or constitutive activation of the 
pathway upstream of Smo, where Smo itself could take on the roll of rate limiting 
reagent in activated Hh signaling. We next asked whether Zfx was wholly or 
partially required for a known Hh-dependent biological process in the context of 
superabundance of Hh ligand or constitutive pathway activation. To answer this 
question, we made use of a previously described assay, where motor neurons 
(MN) are generated in a Hh-dependent fashion in vitro by means the treatment of 
murine ESC with retinoic acid (RA) and Sonic Hedgehog (Shh) or a synthetic Hh 
agonist 148. Zfx-deficient (Zfxnull) ESCs generated fewer MNs than ESCs with 
non-excised conditional Zfx (Zfxflox)(Fig. 27A), especially at low concentrations of 
Hh agonist, as gauged by immunofluorescent staining for the motor neuron 
marker Mnx1 (HB9). Zfxnull ESCs also expressed lower levels of MN- and MN 
progenitor-specific transcription factors Mnx1, Isl1, and Olig2 after Shh-induced 
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differentiation (Fig. 27B), again particularly at low concentrations of Hh agonist or 
recombinant Shh ligand. Replacement of Zfx with a FLAG-tagged allele in Zfxnull 
ESC (ZfxTAG) rescued this defect (Fig. 27B). Meanwhile, expression of a pan-
neuronal tubulin, Tubb3, was largely unaffected in Zfxnull ESC (Fig. 27B). Zfxnull 
ESC also expressed higher levels of Pax6 and Irx3 (Fig. 28), transcription factors 
expressed widely across neuronal progenitor domains more dorsally-fated 
relative to MN progenitors in the developing mouse spinal cord 115, 116. These 
results suggest that the loss of Zfx specifically impairs Hh-dependent 
differentiation of ESC into motor neurons, but not their differentiation into neurons 
generally or differentiation into more dorsally-fated interneurons. 
 
 







































Figure 24. ZFX binds directly to Smo and regulates Smo expression in 
human DAOY MB cells 
(A&B) Zfx binding to Smo in murine and human ChIP-seq. Shown are 
sequencing-read enrichment peaks near TSS of Smo in anti-Zfx ChIP-seq from 
murine ESC (Chen et al., 2008) (A) and near TSS of SMO in anti-ZFX ChIP-seq 
and sheared nuclear lysate control (Input) from DAOY human MB cells (B). 
(C) Expression of ZFX and SMO in DAOY cells after ZFX knockdown. Shown are 
ZFX (left) and SMO (right) expression levels by qPCR 4 days after transduction 
with lentivirus with ZFX-targeting (H2, H3, H4) or scrambled control (SCR) 
shRNA (mean ± SD of triplicate parallel cultures; representative of three 
independent experiments). 
  








Figure 25. Co-deletion of Zfx decreases Smo expression and blunts Hh 
pathway activation in mouse skin after Ptch1 deletion 
Expression levels of Zfx, Smo, and Hh pathway target genes Gli1 and Mycn in 
bulk epidermis and hair follicles from shaved dorsal skin 3 days after topical Tmx 
treatment in Ptch1, Ptch1 Zfx, and Ctrl mice (as described in Fig. 5). Shown are 
normalized expression levels for the indicated genes relative to Ctrl skin as 
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Figure 26. ZfxCKO embryos develop floor plate and motor neuron pools in 
their developing spinal cord. 
 
Embryos were collected at embryonic day 13.5 or 14.5 (E13.5/E14.5) and fixed 
for immunofluorescence staining analysis. Spinal cords from Sox2-Cre- Zfxflox/Y 
embryos (Ctrl) and Sox2-Cre+ Zfxflox/Y embryos were embedded in OCT and 
cryosectioned. Sections were stained with antibodies against the floor plate 
marker, FOXA2/HNF3-β (Seven Hills Bioreagents), or against the motor neuron 
marker HB9/Mnx1. Nuclei were marked with DAPI. 
(A) Floor plate in spinal cord from ZfxCKO embryos. Shown are representative 
micrographs from Ctrl (n = 4) and Sox2-Cre+ Zfxflox/Y (n = 3) E13.5/E14.5 spinal 
cord sections, stained for floor plate marker FOXA2 (green) and with nuclear 
stain DAPI (blue). White arrows indicate FOXA2+ floor plate. 
(B) Developing motor neuron pools from ZfxCKO embryos. Shown are 
representative micrographs from Ctrl (n = 2) and Sox2-Cre+ Zfxflox/Y (n = 1) 
E13.5/E14.5 spinal cord sections, stained for motor neuron marker HB9 (green) 
and with nuclear stain DAPI (blue). White stars indicate motor neuron pools. 
 
  













































































Figure 27. Loss of Zfx impairs Shh-dependent formation of MNs from 
murine ESC in vitro 
Murine ESC carrying conditional (Zfxflox) or null (Zfxnull) Zfx alleles and Zfxnull ESC 
rescued with a tagged Zfx transgene (ZfxTAG) were differentiated into embryoid 
bodies (EB) and treated with synthetic Smo agonist (SAG) or recombinant Shh to 
induce motor neuron (MN) differentiation. 
(A) Immunofluorescence staining for DNA (DAPI, blue), MN progenitors (Olig2; 
red) and MN (Mnx1/HB9, green) in EB following treatment with SAG at the 
indicated concentrations.  
(B) Expression of MN-specific transcription factors in differentiated ESC of the 
indicated genotypes prior to (EB) or 3 days after treatment with the indicated 
concentrations of Shh. Shown are normalized expression levels relative to 
untreated Zfxflox EB as determined by qPCR (mean ± SD of triplicate reactions; 
representative of three independent experiments). 
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Figure 28. Zfx null EBs have increased expression of dorsal spinal cord 
neuronal fate transcription factors in Shh-dependent MN assay in vitro 
Expression levels for the MN-specific transcription factor Mnx1, for two 
transcription factors characteristic of neuronal progenitor pools more “dorsally-
fated” and distal to Shh ligand source in the developing spinal cord (Pax6, Irx3), 
and for the pan-neuronal β3-tubulin (Tubb3). Shown are qPCR results for Zfxflox, 
Zfxnull, and ZfxTAG embryoid bodies (EBs) harvested prior to or following 3 days of 
treatment with retinoic acid (RA) and recombinant Shh ligand. GAPDH was used 
as the control gene, and expression results were normalized to those for 
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Identifying candidates for functional conserved direct targets of ZFX in MB 
 Decreased expression of Smo in mouse skin and human DAOY cells, 
coupled with impaired MN generation from Zfxnull ESC in vitro, all argue in favor 
of an explanation for the effects of Zfx loss in our BCC and MB models that 
centers around transcriptional regulation of Smo. However, recalling results from 
mouse skin and cerebella presented in Chapters I and II, co-deletion of Zfx also 
impaired formation of BCC after Hh pathway activation by constitutively active 
SmoM2 downstream of Smo (Fig. 9), and Zfx loss did not lead to decreased Smo 
levels or blunted Hh pathway activity in P14 cerebella of MB model mice (Fig. 
17). These and other data from BCC and MB systems raise the possibility that 
the Zfx-dependent phenotypes are not explainable solely via regulation of Smo. 
 For this reason, we set out to find additional direct targets of Zfx, identified 
in both mouse and human ChIP-seq, with potential functional relevance in BCC 
and MB. To narrow down the list of direct gene targets to consider, we compared 
the overlap gene-list of Zfx binding targets from both mESC and DAOY cells (Fig. 
22C) with genes in human MB cells whose mRNA expression levels decreased 
along with ZFX loss in human MB cells. We performed microarray-based gene 
expression analysis of DAOY cells at an early time point after transduction with 
lentiviral particles bearing shRNAs targeting ZFX for knockdown. We searched 
for genes whose RNA expression levels behaved similarly to that of ZFX (Fig. 
24C), exhibiting strong reduction by qPCR due to shRNAs H2 and H3 and more 
moderate reduction with shRNA H4. A set of 163 genes whose expression level 
patterns matched that of ZFX in transduced DAOY cells has been identified (Fig. 
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29A). We then compared this gene-list with overlapping conserved direct targets 
of Zfx in mouse and human (Fig. 22C). Of these 163 genes identified by pattern-
matching analysis of microarray data, 68 genes (42%) were bound by Zfx in 
DAOY cells, and 30 genes (18%) were direct binding targets in ChIP-seq from 
both DAOY and murine ESC (Fig. 29B).  
Within this shortlist of 30 conserved direct targets of ZFX in mESC and 
DAOY (Fig. 30A&B), we chose to focus on two genes in particular, DIS3L and 
UBE2J1. Dis3L encodes a cytoplasmic RNA exonuclease with a possible role in 
mRNA degradation 149, 150. Ube2j1 encodes an E2 ubiquitin-conjugating enzyme 
that is thought to participate in the endoplasmic reticulum (ER)-associated 
degradation of misfolded proteins such as MHC class I 151. The expression of 
Dis3L (formerly known as AV340375) strongly depends on Zfx in all examined 
murine cells including HSCs and ESCs (Fig. 30)74 and activated B lymphocytes 
76. The expression of Ube2j1 is also Zfx-dependent in HSCs 74 and B 
lymphocytes 76, although not in ESCs (Fig. 30B)74. These data suggested Dis3L 
and Ube2j1 as candidate genes with potential functional relevance downstream 
of Zfx in both mouse and human. 
 
Knockdown of ZFX targets DIS3L and UBE2J1 impairs human MB growth in vitro 
We next asked if DIS3L and UBE2J1 were required for growth of human 
MB cells in vitro. Before addressing that question head-on, we first sought to 
confirm that DIS3L and UBE2J1 were bound by ZFX directly in a relevant cellular 
context, and that expression of both genes was affected by ZFX loss.  









Figure 29. Identification of conserved Zfx targets by comparison of murine 
and human ZFX ChIP-Seq data from microarray data after ZFX knockdown 
in DAOY human MB 
(A) Downregulated genes (n= 163) identified in pattern matching analysis of 
Affymetrix Gene ST 1.0 array data from DAOY cells after shRNA knockdown.  
(B) Conserved ZFX transcriptional targets. Shown are numbers of pattern-
matching genes from ZFX KD microarray in (A) that had enrichment peaks >1kb 
from TSS in ZFX ChIP-seq from DAOY cells, from murine embryonic stem cells 
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Figure 30. Expression of conserved Zfx targets in mouse HSC and ESC 
(A&B) Heatmaps generated by gene set enrichment analysis (GSEA) software, 
comparing Overlap targets from ZFX KD microarray and ChIP-Seq targets >1kb 
from TSS in DAOY and murine ESC (Figure 27B; n=31) with previously 
published 74 microarray results from murine Zfxflox and ZfxCKO HSC (A) and Zfxflox 
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Visualization of sequence-read enrichment peaks from ChIP-seq confirmed ZFX 
binding near the TSS of both Dis3L (Fig. 31A) and Ube2j1 (Fig. 31B) in both 
murine ESC and human DAOY cells. We tested whether expression levels of the 
targets Dis3L and Ube2j1 were affected in the context of BCC and MB following 
Zfx loss. DIS3L and UBE2J1 expression levels were both decreased after 
shRNA-mediated ZFX knockdown in DAOY cells (Fig. 31C). Moreover, both 
transcripts were reduced ~2-fold after tamoxifen-induced Zfx co-deletion in 
epidermis and hair follicles of treated dorsal skin from the Ptch1-dependent BCC 
model in vivo (Fig. 31D). Collectively with the ChIP-seq binding data in human 
DAOY cells, these data suggest Zfx can directly regulate Dis3L and Ube2j1 
expression in the contexts of BCC and MB models in vivo and in vitro. 
 To determine whether DIS3L or UBE2J1 themselves are required for 
growth of a human MB cell-line in vitro, we transduced DAOY cells with lentiviral 
vectors encoding several shRNAs targeting both genes for knockdown. 
Compared to untreated cells and a control shRNA targeting non-mammalian 
sequence (NonM), all tested shRNAs against DIS3L (4 shRNAs) or UBE2J1 (3 
shRNAs) impaired the growth of DAOY cells (Fig. 32A). Successful knockdown 
DIS3L or UBE2J1 by each in the battery 3-4 shRNAs targeting the respective 
genes was confirmed by qPCR (Fig. 32B). Thus, DIS3L and UBE2J1 represent 
conserved direct binding targets of ZFX that are also required for optimal growth 
of DAOY human MB cells in vitro. These results suggest both genes as 
promising candidates for further research, to determine whether they are 
functionally required across BCC and MB tumors in vivo.   
















































































































Figure 31. Zfx direct targets Dis3L and Ube2j1 and regulates their 
expression in mouse BCC in vivo and human MB in vitro 
(A) Zfx binding to Dis3L in murine and human ChIP-seq. Shown are sequencing-
read enrichment peaks near TSS of Dis3L in anti-Zfx ChIP-seq from murine ESC 
70 (left), and in anti-ZFX ChIP-seq and sheared nuclear lysate control (Input) from 
DAOY human MB cells (right). 
(B) Zfx binding to Ube2j1 in murine and human ChIP-seq. Shown are 
sequencing-read enrichment peaks near TSS of Ube2j1 in anti-Zfx ChIP-seq 
from murine ESC 70 (left), and in anti-ZFX ChIP-seq and sheared nuclear lysate 
control (Input) from DAOY human MB cells (right). 
(C) Expression of DIS3L and UBE2J1 in DAOY cells after ZFX knockdown. 
Shown are DIS3L and UBE2J1 expression levels by qPCR 4 days after 
transduction with lentivirus coding for ZFX-targeting (H2, H3, H4) or scrambled 
control (SCR) shRNA (mean ± SD of triplicate parallel cultures; representative of 
three independent experiments). 
(D) Expression levels of Dis3L and Ube2j1 in bulk epidermis and hair follicles 
from shaved dorsal skin 3 days after topical Tmx treatment in Ptch1, Ptch1 Zfx, 
and Cre- (Ctrl) mice (as described in Fig. 4). Shown are normalized expression 
levels relative to Ctrl skin as determined by qPCR (mean ± SD of 2-4 mice; 
representative of four independent experiments). 
 





























































































Figure 32. Knockdown of DIS3L and UBE2J1 impairs growth of DAOY 
human MB cells in vitro 
DAOY human MB cells were transduced in vitro with Sigma MISSION 
lentiviruses encoding shRNAs targeting DIS3L, UBE2J1, or a non-mammalian 
control gene (NonM).  
(A) Growth curves for DAOY cells transduced with DIS3L- or UBE2J1-targeting 
shRNA lentivirus. Shown are projected cell numbers for untreated DAOY cells 
versus cells transduced with NonM control virus or 3-4 shRNA lentiviruses 
targeting DIS3L (SH1-SH4) or UBE2J1 (SH3-SH5) (mean + SD of triplicate 
parallel cultures; beginning 2 days post- puromycin selection and 4 days post-
transduction). 
(B) Expression of DIS3L and UBE2J1 in DAOY cells after shRNA knockdown. 
Shown are DIS3L (upper) and UBE2J1 (lower) expression levels by qPCR in 
DAOY cells 5 days after transduction with Sigma MISSION lentiviruses coding for 
DIS3L- or UBE2J1-targeting shRNA, respectively, or for NonM control shRNA 
(mean ± SD of triplicate reactions; normalized to expression in untreated DAOY 
cells). 
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Discussion 
 In Chapters I and II, we demonstrated that the transcription factor Zfx is 
required for development of Hh-driven BCC and MB in vivo. In this Chapter, we 
delved deeper into the transcriptional targets of Zfx, to try to understand why it 
was required for development of these two quite different cancers. Using DAOY 
human MB cells, where we had already established a lentiviral shRNA system for 
knocking-down ZFX, we performed anti-ZFX ChIP-seq to identify genomic 
binding sites for ZFX in the context of human MB. We confirmed that ZFX binds 
very close (within 500 bp) to TSS of target genes (Fig. 22A), at sites enriched for 
the ZFX binding motif GGCCT (Fig. 22B, 23). ZFX binding targets in human 
DAOY also had a high degree of overlap with Zfx ChIP-seq targets from murine 
ESC 70, with over 3000 conserved ZFX direct binding targets >1 kb from TSS 
(Fig. 22C).  
 One target gene that was directly bound by Zfx in both mESC (Fig. 24A) 
and human DAOY ChIP-seq (Fig. 24B) was Smo. Identification of Smo, an 
essential component of the Hh pathway, as a direct binding target of ZFX 
suggested an attractively straightforward hypothesis explaining the requirement 
for Zfx in Hh-driven MB and BCC, namely: if Zfx regulates Smo expression in 
these tumors, then loss of Zfx means loss of Smo, and loss of Smo prevents Hh 
pathway activation and Hh-driven tumor progression. This is the same logic that 
spurred small molecule targeting of SMO with compounds like vismodegib (GDC-
0449), which have indeed shown success in regressing Hh-dependent BCC and 
   
130 
MB in human patients 110, 134, 135 136. Consistent with this explanation of BCC and 
MB phenotypes from Zfx loss centering around transcriptional regulation of Smo, 
we previously reported that Zfx co-deletion correlated with decreased Smo 
expression and blunted Hh target gene overexpression in skin from mice treated 
to induce Ptch1 deletion and BCC formation (Fig. 25). Decreased SMO 
expression levels also resulted after ZFX knockdown in human DAOY MB cells in 
vitro (Fig. 24C). Additionally, Zfx-deficient ESC formed fewer MN in a Hh-
dependent MN generation assay in vitro (Fig. 27). To summarize all the points in 
favor, genomic Smo is directly bound by Zfx in both mouse and human, and 
absence of Zfx tracks with decreased Smo expression in BCC in vivo and MB in 
vitro, in addition to impairing a known Hh-dependent differentiation assay in vivo. 
 Unfortunately for the simple hypothesis that Zfx is required in BCC and MB 
entirely because of transcriptional regulation of the Hh signal transducer Smo, 
observations contradicting this interpretation were made in BCC and MB models 
in vivo, as well as in DAOY cells in vitro. In Chapter I, we saw that Zfx loss 
severely impaired BCC development after induction of the activated SmoM2 
allele in the skin (Fig. 9) but did not result in decreased Smo expression or 
blunted Hh pathway (Fig. 10). In Hh-driven MB in the brain, expression levels 
Smo or Hh target genes Gli1 and Mycn were not reduced after Zfx co-deletion 
(Fig. 17). Furthermore, normal cerebellar development in hGFAP-Cre+ Zfxfox/Y 
mice deleting only Zfx (Fig. 19) argued against any generalizable regulation of 
Smo throughout normal cerebellar development, since even partial disruption of 
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Hh pathway functionality causes defective growth and foliation in the developing 
cerebellum 23. Successful Hh-dependent development of floor plate and motor 
neuron pools in spinal cords of ZfxCKO embryos (Fig. 26) also argued against a 
requirement for Zfx in activation of the Hh pathway during normal 
embryogenesis. Finally, while ZFX knockdown correlates with decreased SMO 
expression in DAOY human MB cells, it is unclear that functional Hh signaling is 
active or required in DAOY cells, since treatment with either SMO chemical 
agonist or antagonist did not alter expression of the Hh target GLI1 or affect 
DAOY cell growth in our hands (data not shown).  
 The results from the SmoM2-dependent BCC model in vivo, as well as 
from ZfxCKO cerebella and spinal cords, do not conclusively exclude the possibility 
that Zfx-dependent transcriptional regulation of Smo is crucial in Hh-dependent 
BCC and MB. Deletion of Zfx does not disrupt normal Hh-dependent patterning of 
the cerebellum (Fig. 19) or floor plate and motor neuron pools in the embryonic 
spinal cord (Fig. 26). However, Zfx loss only generates a roughly 2-fold decrease 
in Smo expression in DAOY cells (Fig. 24) and epidermis from the murine BCC 
model (Fig. 25). Smo+/- embryos heterozygous for a null allele of Smoothened are 
phenotypically wild-type 44, 116, suggesting that decreases in Smo levels on the 
order of 2-fold do not block Hh-dependent processes during normal development. 
Moderate decreases in endogenous Smo levels could have significant effects in 
cases of hyperactivated Hh signaling such as Hh-dependent BCC and MB or in 
vitro Hh-dependent motor neuron generation, where levels of Smo could become 
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the rate-limiting agent. A comparable decrease in endogenous Smo expression 
due to Zfx loss could plausibly account for the prevention of SmoM2-dependent 
BCC after Zfx loss (Fig. 9), although changes in endogenous Smo expression 
could not be confirmed by qPCR due to confounding effects of SmoM2 transgene 
overexpression (Fig. 10). 
Nevertheless, given all of these potential contraindications pointing away 
from regulation of Smo as an explanation, we sought to investigate whether 
alternative downstream direct targets of Zfx might explain some of the 
phenotypes we observed in BCC and MB after Zfx loss. We endeavored to 
narrow the list of >3000 direct Zfx binding targets shared in mESC and DAOY 
ChIP-seq, by cross-referencing it against genes whose expression pattern 
mirrors ZFX knockdown in gene expression microarray from DAOY human MB 
cells, in order to identify additional conserved direct targets of Zfx to probe for 
functional significance in MB and BCC. 
 The overlapping list of conserved direct targets of ZFX derived from this 
comparison of ChIP-seq and microarray data was surprisingly short, 
encompassing only 30 genes in total (Fig. 29B, 30). These genes are mostly 
uncharacterized or only minimally characterized in the literature, with a few 
exceptions like FZD6, a Wnt signaling receptor characterized primarily for its role 
in patterning of hairs into whorls 152 but also implicated recently as a marker of a 
stem-cell-like fraction in neuroblastoma 153. We elected to investigate two of the 
minimally characterized conserved target genes, DIS3L and UBE2J1, in greater 
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depth. Neither gene has been linked with cancers in humans, but mutations in 
the DIS3L homolog DIS3L2 have been implicated in an overgrowth disorder 
(Perlman syndrome) and an associated kidney tumor (Wilms tumor) 154, showing 
that a Dis3L-like RNA exonuclease can play a critical role in the context of 
tumorigenesis. Notably, the functions so far ascribed to Dis3L (cytoplasmic RNA 
exonuclease possibly involved in mRNA degradation)149, 150 and to Ube2J1 (E2 
ubiquitin conjugating enzyme involved in misfolded protein degradation in ER)151 
suggest that they could interface with stress pathways (e.g.- proteotoxic stress), 
a hallmark of genes essential in cancers through “non-oncogene addiction” 140. 
 Genomic Dis3L and Ube2j1 are both bound directly by Zfx in mESC and 
human DAOY cells, and transcript levels of both genes are decreased ~2-fold 
after Zfx loss in BCC in vivo and in human MB in vitro (Fig. 31). What’s more, 
lentiviral shRNA-mediated KD targeting either DIS3L or UBE2J1 impaired growth 
of DAOY human MB cells in vitro (Fig. 32). Preliminarily, these results point 
towards a functional requirement for DIS3L and UBE2J1 in a human MB in vitro, 
as well as suggest both genes as prime candidates to explain the non-oncogene 
addiction of Hh-driven BCC and MB to ZFX. However, care must be taken to 
ascertain the specificity of the effect in DAOY cells, as well as its applicability to 
Hh-dependent BCC and MB in vivo. Lentiviral shRNA-mediated KD is notoriously 
prone to non-specific toxicity in transduced cell-lines. To address this, rescue 
experiments in DAOY cells, involving co-delivery of DIS3L-targeting lentiviral 
shRNA and DIS3L-overexpressing retrovirus, are already underway to confirm 
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that DIS3L KD specifically causes growth impairment in human MB in vitro. Over 
the longer run, mice with null or conditionally targetable alleles of Dis3L or 
Ube2j1, or other promising genes off the shortlist of 30 conserved direct targets, 
could be used in concert with Ptch1-dependent BCC and MB models, to identify 
novel elements of a cell-intrinsic molecular machinery defined by Zfx and 
common across two distinct Hh-dependent cancers. 
 
Materials & Methods 
Animals 
Mice with a conditional allele of Ptch1 (Ptch1flox)105 were bred with 
conditional Zfxflox mice74 to generate singly- and doubly-conditional Ptch1flox/flox 
and Ptch1flox/flox Zfxflox/y mice. Tamoxifen (Tmx)-inducible Rosa26-CreERT2 
deleter mice (R26-CreER+) were kindly provided by Dr. Thomas Ludwig, 
Columbia University74. They were bred with Ptch1flox and Ptch1flox Zfxflox mice to 
generate the R26-CreER- Ptch1flox/flox Zfx+/y (Ctrl), R26-CreER+ Ptch1flox/flox Zfx+/y 
(Ptch1), and R26-CreER+ Ptch1flox/flox Zfxflox/y (Ptch1 Zfx) mice used in topical 
Tmx experiments. hGFAP-Cre mice127 were obtained from the Jackson 
Laboratory and crossed with Ptch1flox and Ptch1flox Zfxflox mice to generate 
hGFAP-Cre+ Ptch1flox/flox (Ptch1) and hGFAP-Cre+ Ptch1flox/flox Zfxflox/y (Ptch1 Zfx) 
experimental animals, along with hGFAP-Cre- or hGFAP-Cre+ Ptch1flox/+ 
littermate controls (Ctrl). All animal studies were performed according to the 
investigator’s protocol approved by the Institutional Animal Care and Use 
Committee of Columbia University. 
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Cell Culture 
Zfxflox-neo, Zfxnull, and ZfxTAG murine ESCs and their culture conditions have been 
previously described74.  ESCs were grown on gelatin-coated plates in complete 
DMEM with 5% - 15% Knockout SR (invitrogen) and recombinant leukemia 
inhibitory factor (LIF, Chemicon).   
 Murine ESCs were differentiated into motor neurons (MN) as described148.  
Briefly, ESCs were cultured on gelatin-coated plates in complete DMEM with 5% 
Knockout SR and LIF. Then, 1-2 x 106 ESC were plated in HEMA-coated 100 
mm Petri dishes in differentiation medium (1:1 DMEM/F12: Neurobasal Medium 
with 10% Knockout SR, Invitrogen). Two days after plating in differentiation 
medium, embryoid bodies (EBs) were collected by gravity, rinsed with 1x DPBS 
(Gibco), and split into new Petri dishes containing differentiation medium 
supplemented with 1 µm retinoic acid (RA) and increasing concentrations of the 
synthetic Smo agonist SAG1.3 (Calbiochem) or of recombinant, N-terminal murine 
SHH (R&D Biosystems).  Three days later, treated EBs were collected by gravity 
and either resuspended in TriZol LS reagent (invitrogen) for RNA isolation or 
processed for cryosectioning and immunofluorescence. 
DAOY cells were obtained from the ATCC and propagated in complete 
DMEM medium with 10% FBS, and replated by trypsinization. 
 
RNA Isolation and qPCR 
Total cellular RNA was isolated from samples in 0.5-1 mL TriZol LS 
reagent (Invitrogen).  cDNA was synthesized from 1-2 µg RNA per sample using 
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SuperScript III reverse transcriptase (invitrogen). Quantitative real-time PCR 
(qPCR) assaying for SYBR Green incorporation were run on an Mx3000P 
instrument (Stratagene) using FastStart Universal SYBR Green Master mix 
containing Rox (Roche). Triplicate reactions were run for each sample, and all 
qPCR results were analyzed using the ΔΔCt method. The expression values for 
all genes were normalized to those for the housekeeping genes β-Actin (Actb) or 
GAPDH, and then expressed relative to the indicated control samples. The qPCR 
primers are listed below. 
 
Species Gene Forward Reverse 
Mouse Actb ATCCTGACCCTGAAGTACC TACGACCAGAGGCATACAG 
 GAPDH AAGGTCGGTGTGAACGGATTTG CTCGCTCCTGGAAGATGGTGAT 
 Zfx GCAGTGCATGAACAGCAAGT GCAAGGTGTTCAGGATGGTT 
 Dis3L AGGGGGAAGCCATGGAGAAG GATTTGATGCCCGCTTCCAG 
 Ube2j1 GACGCATAGTACTGCCACCA ATGGCCCCCTCTCCTTTAGT 
 Smo CTCGGACTCGCAGGAGGAAG TCAGGGAAGTGGTCCGGTGT 
 Gli1 CATTGGGGAGGTTGCTCCAG CCGAAGGTGCGTCTTGAGGT 
 Mycn GGAGAGGATACCTTGAGCGACTC CGCCTTGTTGTTAGAGGAGGAAC 
 Mnx1 AGGCGCAGTCGAACCTCTTG TCCATTTCATTCGGCGGTTC 
 Isl1 CAAGCGGTGCAAGGACAAGA CAGGGCGGCTGGTAACTTTG 
 Olig2 CACCTCCTCGTCCACGTCCT GGCGATCTTGGAGAGCTTGC 
 Tubb3 GGCCATTCTGGTGGACTTGG GCCCTGCAGGCAGTCACAAT 
Human GAPDH AAGGTGAAGGTCGGAGTCAACG CCCACTTGATTTTGGAGGGATC 
 Zfx GCAGGATGATGACAAAGGCAAC CAAGGATCAATTTCCGACTCTGTG 
 Dis3L CCAGGACAGGATGCCAATTGTT CGTGGGCAGCTTTTAAATCAGG 
 Ube2j1 GAAACTTGGCAGCCTTCGTG ATGGCAGAGCCACATCCTTC 
 Smo GCTCATCGTGGGAGGCTACTTC AGCATGGTCTCGTTGATCTTGC 
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Tamoxifen Treatment of Dorsal Skin 
Adult male mice of the designated genotypes were shaved across their 
dorsal skin at 7-8 weeks, temporally situating tamoxifen (Tmx) treatment within 
the second telogen of the hair cycle.85 Animals were treated for five consecutive 
days topically with 100 µL per day of 10 mg/mL tamoxifen (Sigma) in acetone 
(i.e. – 1 mg tamoxifen q.d.). For gene expression analysis in bulk epidermis and 
hair follicles, Tmx-treated mice were sacrificed three days after final Tmx 
treatment. Tmx-treated dorsal skin was removed, and 
connective/adipose/vascular tissue was stripped from the dermis in cold PBS 
(Gibco). The remaining dermis and epidermis were floated in 0.25% trypsin - 1x 
EDTA (Gibco), with epidermis/hair follicles up, at 37°C, 7.5% CO2 for 2 hours, 
and bulk hair follicles and epidermis were separated from dermis into DMEM with 
10% FBS using sterile disposable scalpels. Bulk follicles/epidermis were minced, 
collected by centrifugation, and lysed in 2 mL TriZol LS reagent (Invitrogen). At 8-
9 weeks after Tmx-treatment, mice were re-shaved if dorsal hair had regrown, 
and the Tmx-treated patch was removed, flattened, and fixed before processing 
for histology. 
 
shRNA Constructs and Lentiviral Infection of DAOY Cells 
Lentiviral constructs containing Zfx-targeting (H2, H3, H4) and non-
specific (SCR) short hairpin RNAs (shRNAs) in the pLKO.1 backbone were 
purchased from Open Biosystems. To generate high-titer lentivirus, HEK293T 
cells were co-transfected with three plasmids encoding viral packaging proteins 
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(pCMV∆8.9), envelope proteins (pVSVg) and the pLKO.1 shRNA sequences 
using the lipid-based transfection reagent Transit-293 (Mirus, LLC). After 48 
hours incubation at 37°C, transfected cells were shifted to 32°C for 24 hours. 
Then viral supernatant was cleared using 0.45 micron filters and ultracentrifuged 
(50,000 x g, 2 hrs) to concentrate viral particles. 
 Triplicate cultures of 4x105 DAOY cells were plated out overnight and then 
incubated with concentrated lentiviral supernatant and 7 µg/mL polybrene for 16-
24 hrs, for a Mock, virus-less condition and for each lentiviral construct.  Cells 
were allowed to rest for 2 days and then replated and grown henceforth in 
selective media containing 2 µg/mL puromycin (invitrogen).  At 4 or 6 days post-
infection (d.p.i.), plates were washed with 1x DPBS, and cells were collected in 
TriZol LS reagent for gene expression analysis or scraped, collected by 
centrifugation, and lysed in RIPA buffer for Western Blot. 
 Lentiviral shRNA knockdown of ZFX targets DIS3L and UBE2J1 was 
conducted using pre-assembled lentiviral particles obtained from the MISSION 
shRNA library (Sigma-Aldrich). For each lentiviral shRNA construct (3-4 per 
gene, plus a control shRNA targeting non-mammalian sequence [NonM]), 
triplicate cultures of 1x104 DAOY cells were transduced for 16-24 hours in 7 
µg/mL polybrene, with lentiviral densities of 1 TU/cell (NonM) or 10 TU/cell 
(DIS3L- and UBE2J1-targeting constructs), based on manufacturer’s provided 
titers. As above, cells were allowed to rest for 2 days and then replated and 
grown henceforth in selective media containing 2 µg/mL puromycin (invitrogen). 
Transduced cells, along with untreated cells grown without puromycin, were 
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followed for growth curves beginning 5 d.p.i., to ensure that any cell death from 
initial puromycin-selection was excluded. 3x104 cells per shRNA condition were 
also pooled from triplicate cultures at 5 d.p.i. and collected in Trizol LS, for 
subsequent expression analysis by qRT-PCR. Sigma MISSION clone IDs for the 
DIS3L- and UBE2J1-targeting shRNA lentiviral particles used are provided 
below. 
Lentivirus Sigma MISSION ID Sequence 
DIS3L MH1 TRCN0000350506 CCGGGAACAAGGGCCACCACTTATTCTCG
AGAATAAGTGGTGGCCCTTGTTCTTTTTG 
DIS3L MH2 TRCN0000350507 CCGGGCATATCTGACGGAGTTATTTCTCG
AGAAATAACTCCGTCAGATATGCTTTTTG 
DIS3L MH3 TRCN0000315359 CCGGCTGGGTAGCTATTTCGCATATCTCG
AGATATGCGAAATAGCTACCCAGTTTTTG 
DIS3L MH4 TRCN0000315360 CCGGACGCAGCTGTTTGGTACTATCCTCG
AGGATAGTACCAAACAGCTGCGTTTTTTG 
UBE2J1 MH3 TRCN0000368973 CCGGTCCGGCTGTTAAACGTTTAATCTCG
AGATTAAACGTTTAACAGCCGGATTTTTG 
UBE2J1 MH4 TRCN0000320498 CCGGCCACCAAGCATTATTCTCCTACTCG
AGTAGGAGAATAATGCTTGGTGGTTTTTG 
UBE2J1 MH5 TRCN0000368905 CCGGGATGATATACCTACAACATTCCTCG
AGGAATGTTGTAGGTATATCATCTTTTTG 
 
Microarray and ChIP-seq 
RNA for microarray analysis of DAOY human MB cells after ZFX 
knockdown was obtained 4 days after lentiviral transduction from one culture 
replicate for each of the ZFX-targeting shRNA constructs (H2, H3, H4) and non-
targeting “scrambled” control (SCR). Labeled cDNA was analyzed on Affymetrix 
Human Gene 1.0 ST arrays. Pattern-matching genes whose downregulation in 
expression followed the expression profile of Zfx were identified using the 
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pattern-matching analytical tool in NIA Array,132 applied only to microarray data 
for genes with extant Refseq annotations. Heatmaps comparing previously 
published microarray data from ZfxCKO HSC and ZfxKO mESC 74 with the Overlap 
shortlist of conserved ZFX direct targets (Fig. 27) were generated using Gene 
Set Enrichment Analysis software (GSEA 2.0.10).155, 156 
 Sonication-sheared chromatin from DAOY human MB cells was generated 
and isolated using Covaris truChIP High Cell Chromatin Shearing Kit with SDS 
Buffer and S2 Sonicator. ZFX ChIP was performed using rabbit polyclonal 
antibody74 and Protein A Dynabeads (invitrogen), and unprobed sheared 
chromatin was used as a control (Input). Library construction and sequencing 
were performed by the Yale Center for Genome Analysis (New Haven, CT).  For 
comparison with murine ESCs, previously reported Zfx ChIP-seq data were 
downloaded from the NCBI Sequence Read Archive (SRX000552).70 Sequencing 
reads were aligned to the human genome (UCSC hg19) using the short read 
aligner, Bowtie (version 2.0.0).157 Significant ZFX binding enrichment peaks were 
picked using MACS (1.4.0)144 and were visualized using DNAnexus (Mt. View, 
CA). Peak distance to the nearest TSS was determined using PeakAnalyzer 
(version 1.4).158 Unbiased motif analysis was performed on MACS-selected 
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Immunofluorescence 
To analyze MN formation from ESCs in vitro, EBs were collected, washed, 
and then fixed overnight in 4% PFA. EBs were resuspended in PBS with 30% 
sucrose, embedded in OCT, and cryosectioned (16 µm sections).  
 To detect floor plate populations and motor neuron pools in developing 
spinal cord from ZfxCKO embryos, E13.5/E14.5 Sox2-Cre+ Zfxflox/Y embryos (and 
Sox2-Cre- littermates) were fixed overnight in 4% PFA and processed for 
croysectioning. Cryosections were stained with antibodies raised against the floor 
plate marker FOXA2 (Seven Hills Bioreagents) or the motor neuron marker HB9 
(a gift from C. Henderson).  
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Zfx is required for tumorigenesis in two distinct Hh-dependent cancers 
The transcription factor Zfx has previously been shown to be essentially 
required for the self-renewal, but not differentiation, of multiple distinct stem cell 
types, murine and human ESC and murine adult HSC 74, 75. The role of Zfx in the 
context of malignancy, however, remains unclear. We hypothesized that Zfx 
could also be required to facilitate aberrant self-renewal programs in certain 
cancers, particularly in tumors originating from stem/progenitor pools in their 
tissue-of-origin. To test this hypothesis, we generated Hh-driven BCC and MB in 
vivo using conditional deletion of the Hh inhibitory receptor Ptch1 11, 20, with or 
without concomitant deletion of Zfx. We found that Zfx co-deletion prevented Hh-
dependent BCC formation and significantly delayed Hh-dependent MB formation 
in our tumor models in vivo. 
 Our results showing a partial or complete requirement for Zfx for MB and 
BCC progression contrast with, but do not necessarily contradict, the results from 
O’Donnell et al. (2012) identifying Zfx as a potential tumor suppressor in MYC-
dependent liver cancer. Indeed, we found Zfx to be dispensable for PTEN-
dependent glioblastoma development in vivo. The transcriptional program 
governed by Zfx may have different biological significance in different cancer 
cells, being dispensable for or even inhibitory to cancer growth in one context 
while being essential for growth in another. In our case, given the observed 
requirement for Zfx across Hh-dependent MB and BCC models in vivo, we 
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conclude that Zfx and its targets constitute a novel cell-intrinsic machinery both 
shared and required by at least two distinct Hh-dependent cancers. 
 
Zfx regulation of Hh signal transducer Smo in BCC and MB  
 Zfx transcriptional regulation of the Hh signal transducer gene Smo is one 
possible explanation for these effects on Hh-driven cancers. We demonstrated 
that Zfx binds directly to Smo adjacent to its TSS in both mouse and human cell 
lines using ChIP-seq. Compellingly, we also found that the Zfx-dependent 
prevention of BCC formation in the skin correlated with decreased Smo levels 
and blunted Hh target genes normally overexpressed at early timepoints after 
induction of Ptch1 deletion. A decrease in Smo levels and consequent block of 
downstream target overexpression is a plausible cause of prevention of Hh-
dependent BCC. In mice that develop BCC due to overexpression of the Hh 
transcriptional activator Gli2, BCC are not maintained after the removal of Gli2 
overexpression (and Hh pathway hyperactivation) 22. Furthermore, the essential 
requirement for Smo for the Hh pathway activation driving BCC is the rationale 
behind developing small molecule inhibitors of Smo in order to treat this disease, 
inhibitors which have already shown promise in regressing tumors in human 
patients and been approved by the FDA for use in treating metastatic or locally 
advanced BCC 110, 136, 137 . 
 Zfx does not, however, seem to be generally required for all Smo 
expression during embryonic or post-natal development. Our laboratory 
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previously reported the observation that mice deleting Zfx throughout the 
embryo-proper are born grossly normal in appearance but die perinatally of 
causes unknown 74. Here, we also showedZfxCKO embryos also successfully 
develop floor plate and motor neuron pools in their ventral spinal cord, patterning 
events known to depend on active Hh signaling 55, 116. These results are 
incompatible with any premise that Zfx is necessary for all Smo expression 
during normal development generally, since Shh -/- or Smo -/- embryos develop 
massive skeletal and nervous system defects (e.g.- holoprosencephaly) 26, none 
of which were on display in perinatal ZfxCKO pups. Furthermore, our data showed 
that Zfx deletion throughout the brain of hGFAP-Cre+ Zfxflox/Y pups did not grossly 
impair cerebellar development, as one would expect if Zfx controlled Smo in the 
post-natal cerebellum, given the dependence of normal cerebellar foliation and 
size on Hh signaling 23, 24. 
 The striking decrease in Smo expression and blunting in Gli1 and Mycn 
overexpression in the Ptch1-dependent BCC model was simply absent in our 
other in vivo models of Hh-driven BCC. Treated skin from the SmoM2-dependent 
BCC model and P14 cerebella from the Ptch1-driven MB model both showed no 
difference in Smo expression or Hh target gene overexpression after Zfx deletion. 
In the case of SmoM2-driven BCC, failure to detect changes in Smo expression 
levels does not necessarily mean that Zfx loss had no effect on endogenous Smo 
expression, since our qPCR for Smo could not distinguish between the 
endogenous mRNA and the SmoM2 transgenic mRNA. Since Smo dimerization 
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appears to be required during Hh pathway activation 48, endogenous Smo could 
have an essential role in SmoM2-driven BCC tumor progression as a 
dimerization partner with the transgenic activated SmoM2 allele. Thus, it remains 
a possibility that loss of Zfx impairs SmoM2-driven BCC via decreasing 
endogenous Smo expression. 
The phenotype from Zfx loss was far weaker in general in Hh-driven MB 
than in the BCC models in the skin. Quantitative decrease in MB tumor size could 
be observed in P7 cerebella, and tumor progression was delayed enough by Zfx 
loss to enhance survival times for a fraction of the doubly-deleting mice. 
However, when looking at survival curves and P7 and P14 cerebellar sections, 
we are in fact observing fairly late events for this MB model. The hGFAP-Cre 
transgene driving Ptch1 deletion turns on at E13.5, causes EGL expansion at 
least as early as E16.5, and kills mice via Hh-driven MB by ~4 weeks of age 11, 
127. Therefore, one possible explanation for the difference in phenotypes from Zfx 
loss observed in Hh-driven MB versus BCC is that Smo (or another relevant Zfx 
target) is only controlled by Zfx in the MB model over a temporally restricted 
window, early on after Cre-mediated excision begins. As the window closes, the 
cells would be acquiring the ability to discard the requirement for Zfx to express 
Smo or its other functionally relevant target, potentially via compensatory 
transcriptional activation from a redundant or alternative transcription factor. By 
the time MB are observed at P7 or P14, MB that lost Zfx would no longer be 
substantially different molecularly from those that had not, instead growing at the 
   
147 
same pace as the MB with wild-type Zfx. This hypothesis is supported by our 
microarray analysis of P14 MB cerebella, which revealed very few expression 
changes between Ptch1 single-knockout and Ptch1 Zfx double knockout 
cerebella. Generating Ptch1-dependent MB using an inducible, GNP-specific Cre 
recombinase like Math1-CreER could test this explanation by inducing a more 
slowly progressing MB disease under temporal control via tamoxifen 
administration, allowing for easier observation of early events in incipient MB just 
after Zfx co-deletion. 
 
Identification of conserved direct transcriptional targets of ZFX, DIS3L  and 
UBE2J1, and their functional requirement for growth of human MB cells in vitro 
 Alternately, the differences in phenotype from Zfx loss between MB and 
BCC models could also be explainable if the effects in MB were mediated by 
different downstream Zfx targets besides Smo. We generated a shortlist of 30 
conserved direct transcriptional targets of ZFX, by comparing ChIP-seq targets in 
murine ESC and DAOY human MB cells with genes whose expression 
decreased along with ZFX in DAOY human MB cells after lentiviral KD. From this 
list, we focused on two relatively uncharacterized targets, DIS3L and UBE2J1, 
whose expression also depends on Zfx in murine ESC and HSC 74. The functions 
of DIS3L (cytoplasmic RNA exonuclease with a possible role in mRNA 
degradation) 149, 150 and UBE2J1 (E2 ubiquitin-conjugating enzyme involved in 
ER-associated degradation of misfolded proteins) 151 suggest that disregulation 
of either gene could impact proteoxic or other stress pathways, a result 
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consistent with the non-oncogene addiction 140 to Zfx evident in Hh-driven BCC 
and MB in vivo. Also, the discovery that DIS3L2, a DIS3L homolog, is implicated 
in an overgrowth syndrome and Wilm’s tumor lends credence to the 
consideration of an uncharacterized RNA exonuclease for a possible role in 
cancer 154. 
 Preliminary lentiviral shRNA knockdown experiments targeting DIS3L and 
UBE2J1 suggest that each is required for optimal growth of DAOY human MB 
cells in vitro, pending verification of the specificity of the RNAi-mediated growth 
defect with overexpression-based rescue experiments. Other targets from the 30 
gene target list could also be tested in human MB cells in vitro. Even better, gene 
expression microarray data from treated skin in the BCC mice or cerebella in MB 
mice shortly after Zfx co-deletion, when compared with direct Zfx binding targets 
from mouse and human ChIP-seq, could generate superior shortlists likely 
enriched in targets relevant for Hh-dependent MB and BCC in vivo. Ideally, the 
most promising conserved direct targets of ZFX, after testing in in vitro cell lines 
by shRNA knockdown, could be eventually tested in mouse models of Hh-
dependent BCC and MB, using knockout or conditional mice for the specific 
target genes, to conclusively identify the downstream targets of Zfx that comprise 
its required gene program in two very different Hh-dependent cancers. 
 
Conclusion 
 We report that the transcription factor Zfx is required for the development 
of two highly disparate Hh-induced tumors, BCC and MB. Our results suggest 
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that this effect may be due at least in part to direct regulation by Zfx of the Hh 
pathway signal transducer Smo. An analysis of Zfx genomic targets in mouse 
and human also revealed a conserved set of Zfx target genes, some of which 
were required for growth of a human MB cell line in vitro. A more complete 
understanding of the relevant functional targets of Zfx in the context of MB and 
BCC could bear fruit with regard to molecular targeting of these malignancies. 
Trials have already shown promising results from molecular targeting of Smo in 
BCC and MB 110, 134, 135, 136, 137. However, resistance mutations to small molecule 
therapies directed against Smo have already been documented 138, and 
treatment of Hh-driven MB with Smo inhibitors runs the risk of serious 
developmental side-effects, since most MB occur in young children where Hh 
signaling is required for ongoing normal development of their cerebellum, bones, 
and other tissues 7, 139. Practically, treatment with Smo inhibitors like vismodegib 
(GDC-0449) also poses problems in adult patients. Phase II trial data with 
vismodegib in BCC patients revealed that delivery of Smo small molecule 
inhibitor resulted in non-life-threatening but highly unpleasant side effects such 
as alopecia and dysgeusia in the great majority of cases 136. Future identification 
of the precise downstream targets with functional relevance in a Zfx-defined cell-
intrinsic program shared by these two cancers offers the promise of yielding 
alternative druggable molecules for treatment of both BCC and the Hh-
dependent subtype of MB - - treatments which could avoid these developmental 
pitfalls and adverse side effects. 
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